Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 8823. Отображено 100.
12-01-2012 дата публикации

Encapsulated cure systems

Номер: US20120010364A1
Принадлежит: Appleton Papers Inc

Encapsulated cure systems are provided wherein a curative is incorporated into a solid or semi-solid carrier material whereby mere fracturing or failure of the capsule wall encapsulating such cure systems will not provide for or allow sufficient release of the curative. Also provided are adhesive systems incorporating said encapsulated cure systems.

Подробнее
19-01-2012 дата публикации

Electrospinning manufacture for drug carriers

Номер: US20120013046A1
Принадлежит: I-SHOU UNIVERSITY

An electrospinning manufacture for drug carriers is disclosed. The method comprises a preliminary step mixing a predetermined drug, an alginate, and a saline to obtain a mixture; an electric field establishing step providing a collection plate and an emitter filled with divalent cation agent and the mixture individually, wherein an electric field is applied to the collection plate and the emitter to form a voltage therebetween; and an electrospinning step sequentially dropping the mixture from the emitter into the divalent cation agent filled in the collection plate via the driving of the electric field, triggering a crosslinking-gelating reaction between the divalent cation and the alginate, wherein a plurality of gel particles is produced for a coating of the predetermined drug presenting a drug carrier performance.

Подробнее
19-01-2012 дата публикации

Process for preparing a core-layer material having good mechanical strength

Номер: US20120016170A1
Принадлежит: IFP Energies Nouvelles IFPEN

A process is described for preparing a spherical material comprising a porous core coated with a continuous and homogeneous porous layer, the degree of attrition of said material being less than 20%. Said preparation process comprises a) bringing a bed of spherical particles constituting the core of said material into contact with a suspension containing an inorganic binder in order to form a solid having a pre-layer around said core; b) bringing the solid derived from step a) into contact, in a stream of hot air, with a powder constituted by spherical particles of an inorganic oxide and a suspension containing an inorganic binder and an organic binder in order to form a solid the core of which is coated with at least one continuous and homogeneous porous layer, the ratio of the (mass of anhydrous inorganic binder/volume of powder particles) being in the range 0.05 to 1 g.mL −1 ; c) drying the solid derived from said step b); and d) calcining the solid derived from said step c).

Подробнее
10-05-2012 дата публикации

Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein

Номер: US20120114707A1
Автор: Trevor P. Castor
Принадлежит: Individual

This invention is an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins or other useful substances, and a polymer sphere apparatus. The invention is also methods of purifying protein-containing-polymeric-microspheres from unused polymer, and an apparatus therefore.

Подробнее
23-08-2012 дата публикации

Preparation of polyphosphazene microspheres

Номер: US20120214951A1
Принадлежит: Individual

Methods of producing polyphosphazene microspheres comprising admixing aqueous solutions of a water-soluble polyphosphazene and an organic amine, or salt thereof, are disclosed.

Подробнее
21-03-2013 дата публикации

Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances

Номер: US20130071480A1

Particles having a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups. 1. A method of preparing particles encapsulating a hydrophobic active substance , comprising: dissolving a biodegradable polymer in en organic phase with the hydrophobic active substance to be encapsulated,', 'dissolving an amphiphilic hyaluronan in an aqueous phase, the aqueous phase being a dispersing medium for the organic phase, and', 'mixing the organic phase and the aqueous phase;, 'preparing a single emulsion includingevaporating off an organic solvent; andrecovering the particles encapsulating the hydrophobic active substance.2. The method of claim 1 , further comprising washing the particles with water.3. The method of claim 1 , farther comprising subjecting the particles to centrifugation or lyophilization.4. The method of claim 1 , wherein the organic phase is a solvent that is barely soluble in water.5. The method of claim 4 , wherein the organic solvent is methylene chloride or ethyl acetate.6. The method of claim 1 , further comprising incorporating a diagnostic compound into the particles.7. The method of claim 6 , wherein the diagnostic compound comprises at least one substance capable of being detected by X-rays claim 6 , fluorescence claim 6 , ultrasound claim 6 , substances nuclear magnetic resonance claim 6 , or radioactivity.8. The method of claim 6 , wherein incorporating the diagnostic material occurs during formation of the particles claim 6 ,9. A method of preparing particles encapsulating a hydrophilic active material claim 6 , comprising: the organic phase contains a biodegradable organosoluble polymer, and', 'the first aqueous phase contains the hydrophilic active material to be encapsulated;, ' ...

Подробнее
28-03-2013 дата публикации

ENCAPSULATION DEVICE, MEDICAL CAPSULES, AND ENCAPSULATION METHOD

Номер: US20130078308A1
Принадлежит: SEIKO EPSON CORPORATION

An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in which the first liquid is injected toward a liquid film of the second liquid retained by the liquid film holder to form a core, the core is wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, and the shell is made in contact with the third liquid to induce chemical reaction. 1. An encapsulation device comprising:a fluid injection device that injects a first liquid forming a core;a liquid film holder that holds in film form a second liquid forming a shell containing the core; anda liquid contact device that makes the shell in contact with a third liquid,the first liquid being injected toward a liquid film of the second liquid retained by the liquid film holder to form a core,the core being wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, andthe shell being made in contact with the third liquid to induce chemical reaction.2. The encapsulation device according to claim 1 , whereinthe liquid contact device has a liquid reservoir that reserves the third liquid in liquid form, andthe second liquid is made in contact with the third liquid by making the core wrapped with the second liquid to enter the liquid reservoir.3. The encapsulation device according to claim 1 , whereinthe liquid contact device has a mist generator that mists the third liquid in mist form, andthe second liquid is made in contact with the third liquid by misting the third liquid from the mist generator to an area, toward which the core wrapped with the second liquid is moved.4. The encapsulation device according to claim 2 , whereinthe second liquid is an aqueous solution containing a ...

Подробнее
11-04-2013 дата публикации

LOCALIZATION OF AGENTS AT A TARGET SITE WITH A COMPOSITION AND AN ENERGY SOURCE

Номер: US20130090591A1

A method for localizing delivery of an agent to a target site in a subject is provided. The method allows accumulation and/or release of the agent at the target site in the subject through the use of an energy source. 1. A method for localized delivery of an agent to a target site , comprising:administering a composition to a subject, wherein the subject comprises the target site and the composition comprises an agent-transition metal complex; andirradiating the target site with an energy source, the irradiating causing accumulation of the agent-transition metal complex at the target site or release of the agent-transition metal complex from the composition at the target site, thereby producing localized delivery of the agent to the target site.2. The method of claim 1 , wherein the administered composition further comprises a liposome comprising a 63:7:25:5 molar ratio of DPPC:DSPC:chol:DSPE-PEG2k claim 1 , wherein the liposome comprises the complex claim 1 , wherein the agent is doxorubicin claim 1 , wherein the transition metal is copper (II) claim 1 , wherein the energy source is ultrasound claim 1 , wherein the target site comprises a tumor claim 1 , and wherein the method further comprises administering rapamycin to the subject.3. The method of claim 1 , wherein the agent is doxorubicin.4. The method of claim 1 , wherein the agent is an anthracycline.5. The method of claim 4 , wherein the anthracycline is selected from the group consisting of: daunorubicin claim 4 , doxorubicin claim 4 , epirubicin claim 4 , idarubicin claim 4 , mitoxantrone claim 4 , valrubicin claim 4 , and irinotecan.6. The method of claim 3 , wherein the transition metal is copper.7. The method of claim 6 , wherein the molar ratio of doxorubicin to copper in the composition is 2:1.8. The method of claim 6 , wherein the molar ratio of doxorubicin to copper in the composition is 1:1.9. The method of claim 3 , wherein the doxorubicin concentration in the composition is less than 50 mM claim 3 ...

Подробнее
18-04-2013 дата публикации

PROCESS FOR THE PREPARATION OF CONTROLLED-RELEASE SOLID FORMULATIONS CONTAINING OXCARBAZEPINE, AND FORMULATIONS OBTAINABLE BY SAID PROCESS

Номер: US20130095149A1
Принадлежит: ARCHIMICA S.R.L.

The present invention relates to a process for the preparation of controlled-release solid oral pharmaceutical formulations of oxcarbazepine, and the pharmaceutical formulations obtainable by said process. 1. A process for the preparation of controlled-release solid oral pharmaceutical formulations of oxcarbazepine which comprises:a) dissolving the oxcarbazepine and mixtures of mono-, di- and triglycerides in an organic solvent miscible with water to obtain a solution;b) adding an aqueous suspension of water-insoluble excipients to the solution obtained in a) to obtain a wet microcrystalline co-precipitate;c) adding any water-soluble excipients to the wet microcrystalline co-precipitate obtained in b) and granulating the resulting mixture; andd) compressing or distributing the granulate obtained in c) in the pharmaceutical administration form.2. The process as claimed in claim 1 , wherein step b) is performed at a temperature of between 0 and 8° C.3. The process as claimed in claim 2 , wherein the microcrystalline co-precipitate obtained has an average particle-size distribution of approximately 50 μm.4. The process as claimed in claim 1 , wherein the organic solvent miscible with water is dimethylformamide.5. The process as claimed in claim 1 , wherein the water-insoluble excipients are selected from microcrystalline cellulose and derivatives thereof claim 1 , methylcellulose claim 1 , hydroxypropyl methylcellulose claim 1 , ethylcellulose claim 1 , pineapple fibres claim 1 , talc claim 1 , colloidal silicon dioxide claim 1 , calcium phosphate claim 1 , magnesium phosphate claim 1 , milk protein claim 1 , soy proteins and gelatin.6. The process as claimed in claim 1 , wherein the water-soluble excipients to be added at step c) are selected from mannitol claim 1 , xylitol claim 1 , maltodextrins claim 1 , sodium carboxymethylcellulose claim 1 , polyethylene glycols claim 1 , agar agar and mixtures thereof.7. Pharmaceutical compositions obtainable by the process as ...

Подробнее
06-06-2013 дата публикации

BECLOMETHASONE DIPROPIONATE COMPOSITIONS IN MODIFIED-RELEASE GASTRO-RESISTANT MICROSPHERES AND PROCESS FOR OBTAINING THEM

Номер: US20130142880A1
Автор: LABRUZZO Carla
Принадлежит: SOFAR SPA

The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions. 1. A pharmaceutical composition in modified-release gastro-resistant microspheres , each microsphere comprising:a) a core consisting of a microsphere of inert material;b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient;c) a second modified-release gastro-resistant coating.2. A pharmaceutical composition according to claim 1 , wherein said microsphere of inert material has an average particle size of between 100 and 1000 microns claim 1 , preferably between 350 and 500 microns.3. A pharmaceutical composition according to claim 2 , wherein said inert material is a diluent.4. A pharmaceutical composition according to claim 3 , wherein said diluent is selected from microcrystalline cellulose claim 3 , saccharose claim 3 , corn starch claim 3 , lactose and/or a mixture thereof.5. A pharmaceutical composition according to claim 1 , wherein said at least one physiologically acceptable excipient is selected from suspending agents and/or glidants claim 1 , filming agents claim 1 , plasticizing agents and/or a mixture thereof6. A pharmaceutical composition according to claim 5 , wherein said suspending agents and/or glidants are selected from colloidal anhydrous silica claim 5 , talc and/or a mixture thereof.7. A pharmaceutical composition according to claim 5 , wherein said filming agents are selected from alkyl cellulose ...

Подробнее
25-07-2013 дата публикации

METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES

Номер: US20130189365A1
Принадлежит: MANNKIND CORPORATION

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle. 1. A method of promoting binding of an active agent to a preformed crystalline diketopiperazine microparticle in suspension comprising:modifying the chemical potential of the active agent by modifying the structure, flexibility, rigidity, solubility or stability of the active agent to allow for an energetically favorable interaction between the active agent and the preformed crystalline diketopiperazine microparticle independent of removal of solvent;wherein said modifying step causes adsorption of said active agent onto a surface of said preformed crystalline diketopiperazine microparticle to provide a coating of said active agent on said preformed crystalline diketopiperazine microparticle, said preformed crystalline diketopiperazine microparticle does not comprise an active agent, and said active agent comprises an antibody or fragment thereof.2. The method of wherein the antibody or fragment thereof is humanized or chimeric.3. The method of wherein the antibody or fragment thereof comprises F(ab) claim 1 , F(ab)2 claim 1 , or a single-chain antibody.4. The method of wherein the antibody or fragment thereof is fused to a polypeptide.5. The method of wherein the antibody or fragment thereof can recognize a disease-associated antigen.6. The method of wherein the disease-associated antigen is a tumor-associated antigen or an infectious pathogen-related antigen.7. The method of wherein the disease-associated antigen is one of cancer antigens claim 5 , cytokines claim 5 , infectious agents claim 5 , inflammatory mediators claim 5 , hormones claim 5 , and cell surface antigens.8. The method of wherein the antibody or fragment thereof is one of anti-SSX-2(synovial sarcoma claim 7 , X breakpoint 2) claim 7 , anti-NY-ESO-1 (esophageal tumor associated antigen) ...

Подробнее
01-08-2013 дата публикации

WATER-SOLUBLE MELOXICAM GRANULES

Номер: US20130193028A1
Принадлежит: BOEHRINGER INGELHEIM VETMEDICA GMBH

Water soluble meloxicam granules include meloxicam, a salt forming agent which forms the meglumine, sodium, potassium, or ammonium salt of meloxicam, a binder, a sugar or sweetener, and a carrier, and a flavoring agent. 1. A method of treating animals comprising administering water soluble granules to an animal , the water soluble granules comprising meloxicam; a salt forming agent operable to form a meloxicam salt; a binder; and a carrier.2. The method according to further comprising dissolving the water soluble granules in water prior to administration.3. The method according to further comprising mixing the water soluble granules with animal feed prior to administration.4. The method according to claim 1 , wherein the salt forming agent is selected from the group consisting of meglumine claim 1 , sodium claim 1 , potassium claim 1 , or ammonium meloxicam salt.5. The method according to claim 1 , wherein the salt forming agent is meglumine.6. The method according to claim 1 , wherein the binder is selected from hydroxypropylmethylcellulose claim 1 , polyvinylpyrrolidone claim 1 , gelatine claim 1 , starch claim 1 , or polyethylene glycol ether.7. The method according to claim 6 , wherein the binder is present in an amount of 20 mg/g to 150 mg/g.8. The method according to claim 1 , wherein the water soluble granules are administered in conjunction with antibiotic treatment.9. The method according to claim 1 , wherein the animal includes horses claim 1 , pigs claim 1 , cattle claim 1 , dogs claim 1 , or cats.10. The method according to claim 1 , wherein the meloxicam granules comprises meloxicam claim 1 , meglumine claim 1 , hydroxypropylmethylcellulose claim 1 , povidone claim 1 , and glucose monohydrate.11. The method according to claim 1 , wherein the granules possess a particle size distribution of 125 μm to 500 μm.12. The method according to claim 1 , wherein:the salt forming agent is meglumine;the molar ratio of meglumine and meloxicam is 9:8 to 12:8.13. An ...

Подробнее
01-08-2013 дата публикации

METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES

Номер: US20130195965A1
Принадлежит: PACIRA PHARMACEUTICALS, INC.

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated. 1. An atomizing nozzle apparatus , comprising:a first fluid conduit and a second fluid conduit each having at least one entrance orifice and at least one exit orifice;a fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and connecting to the at least one exit orifice of the first fluid conduit; anda third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the fluid contacting chamber.2. The atomizing nozzle of claim 1 , wherein the fluid contacting chamber connects to the at least one exit orifice of the second fluid conduit.3. The atomizing nozzle of claim 1 , wherein the at least one exit orifice of the fluid contacting chamber and the at least one exit orifice of the third fluid conduit are flush.4. The atomizing nozzle of claim 1 , wherein the at least one exit orifice of the fluid contacting chamber is recessed within the at least one exit orifice of the third fluid conduit.5. The atomizing nozzle of claim 1 , wherein the at least one exit orifice of the fluid contacting chamber extends beyond the at least one exit orifice of the third fluid conduit.6. The atomizing nozzle of claim 1 , wherein the first fluid conduit and the second fluid conduit are co-axial for a first portion of the first fluid conduit ...

Подробнее
01-08-2013 дата публикации

New Particles of Tetracyclines and Protecting Agent

Номер: US20130195986A1
Принадлежит: HOVIONE INTER LTD

Particles containing a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant, formulations containing the same and their use in the treatment of infectious diseases are described. Methods of encapsulation of a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant are also disclosed. 1. A particle comprising a tetracycline and an antioxidant characterized in that the tetracycline and the antioxidant are encapsulated in a polymeric material , wherein , in use , the tetracycline and the antioxidant are delivered simultaneously in precise and fixed proportions.2. A particle according to characterized in that the tetracycline is doxycycline claim 1 , minocycline claim 1 , tigecycline or tetracycline or one of their pharmaceutically acceptable salts.3. A particle according to wherein the tetracycline is doxycycline or minocycline or a pharmaceutically acceptable salt thereof.4. A particle according to claim 1 , characterized in that the antioxidant is ascorbic acid (vitamin C); a tocopherol or a tocotrienol such as vitamin E; a carotene; a flavonoid such as quercetin or a mixture of one or more of the above.5. A particle according to claim 1 , wherein the antioxidant is ascorbic acid (vitamin C) or quercetin.6. A particle according to claim 1 , characterized in that the polymer is a polysaccharide such as a starch claim 1 , a maltodextrine or gum arabic claim 1 , a lipid such as stearic acid or a mono or diglyceride claim 1 , a protein such as gelatin claim 1 , casein or soy claim 1 , a polymer such hydroxypropylmethyl cellulose or its derivatives claim 1 , polymethacrylate or its derivatives claim 1 , polyvinylpyrrolidone or its derivatives claim 1 , polyethyleneglycol or its derivatives; or a mixture of one or more of the above.7. A particle according to wherein the polymer is a hydropropylmethyl cellulose derivative such as hydropropylmethyl cellulose acetate succinate.8. A particle according to claim 1 , ...

Подробнее
15-08-2013 дата публикации

Novel method for producing nanocapsules in the absence of an organic solvent, and nanocapsules produced thereby

Номер: US20130207286A1
Принадлежит: Individual

A method for preparing an aqueous suspension of nanocapsules comprising an oily core surrounded by a polymeric shell, comprises mixing first and second phases, wherein the first oily phase comprises a hydrophobic polymer, an oil or a mixture of oils, at least one active ingredient, and a surfactant TA 1 . The oily phase is brought to a temperature T 1 higher than the melting point of the hydrophobic polymer, the hydrophobic polymer being miscible, at this temperature T 1 , with the mixture of the surfactant TA 1 and the oil or mixture of oils, and the active ingredient being miscible, soluble or solubilized in the mixture of the surfactant TA 1 and the oil or mixture of oils. The second polar phase comprises a hydrophilic polymer in the form of a hydrogel in an aqueous solution containing a surfactant TA 2 , to form the nanocapsules in an aqueous suspension.

Подробнее
19-09-2013 дата публикации

Anionic lipids and lipid nano-structures and methods of producing and using same

Номер: US20130243688A1

Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same.

Подробнее
26-09-2013 дата публикации

Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle

Номер: US20130251788A1
Автор: Kunishima Munetaka
Принадлежит: JAPAN SCIENCE AND TECHNOLOGY AGENCY

Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion. In the membrane fusion, for example, fusion can occur without leakage of the contents of the bilayer membrane vesicle. 1. A method of inducing a phase transition of a bilayer membrane vesicle , comprising:preparing a bilayer membrane vesicle, in which the bilayer membrane vesicle comprises as components of the membrane:(a) a fatty acid salt having 6 to 20 carbon atoms;(b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and(c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane; andadding a dehydrating condensing agent or a dehydrating condensing agent precursor to the bilayer membrane vesicle.2. The method of claim 1 , wherein the (b) alcohol or amine compound is a dihydric alcohol represented by the following formula I:{'br': None, 'sup': '1', 'sub': 2', '2, 'R—NH—CH—CH(OH)—CHOH\u2003\u2003(I)'}{'sup': '1', 'wherein Ris an alkyl group having 6 to 20 carbon atoms, an alkenyl group having 6 to 20 carbon atoms, or an alkynyl ...

Подробнее
17-10-2013 дата публикации

METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS

Номер: US20130273146A1
Принадлежит:

Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation. 2. The method of claim 1 , wherein the charged lipid in the preformed lipid vesicles comprises a cationic lipid and the therapeutic agent is an anionic therapeutic agent.3. The method of claim 2 , wherein the therapeutic agent is a polynucleotide.4. The method of or claim 2 , wherein the cationic lipid is selected from the group consisting ofdioleyl-N,N-dimethylammonium chloride (“DODAC”);N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (“DOTMA”);N,N-distearyl-N,N-dimethylammonium bromide (“DDAB”); N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (“DOTAP”);3β-(N-(N′,N′-dimethylaminoethane)-carbamoyl)cholesterol (“DC-Chol”);N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (“DMRIE”);cationic liposomes comprising DOTMA and 1,2-dioleoyl-sn-3-phosphoethanolamine (“DOPE”);cationic liposomes comprising N-(1-(2,3-dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethylammonium trifluoroacetate (“DOSPA”) and DOPE;cationic lipids comprising dioctadecylamidoglycyl carboxyspermine (“DOGS”) in ethanol;N-(2,3-dioleyloxy) ...

Подробнее
14-11-2013 дата публикации

METHOD FOR ENCAPSULATING PARTICLES

Номер: US20130302429A1
Принадлежит: NANYANG TECHNOLOGICAL UNIVERSITY

The present invention relates to a method for encapsulating particles of a water-insoluble material within a capsule of a water-insoluble polymer, comprising (a) dispersing particles of the water-insoluble material or a solution containing the water-insoluble material in a first aqueous phase containing a first surfactant to obtain a first dispersion; (b) collecting the particles of the water-insoluble material coated with the first surfactant; (c) washing the collected particles; (d) adding the washed surfactant-coated water-insoluble material particles to a polymer solution containing the water-insoluble polymer of the capsule to obtain a polymer mixture; and (e) dispersing the polymer mixture in a second aqueous phase containing a second surfactant to obtain a second dispersion comprising the particles of the water-insoluble material encapsulated within the capsule of the water-insoluble polymer. 2. (canceled)3. (canceled)4. The method of claim 1 , wherein the particles of the water-insoluble material or the solution of the water-insoluble material as used in step (a) further comprises a marker substance and/or therapeutic agent.5. (canceled)6. (canceled)7. The method of claim 4 , wherein the solution of the water-insoluble material is formed by:dissolving the water-insoluble material in a first volume of a suitable solvent and combining the solution with a second volume of a suitable solvent containing the marker substance or therapeutic agent.8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. The method of claim 1 , wherein particles of the water-insoluble material further comprise particles of a further water-insoluble material.13. The method of claim 12 , wherein the further water-insoluble material comprises or consists of at least one polymer.14. The method of claim 12 , wherein the further water-insoluble material comprises or consists of iron oxide or titanium dioxide.15. The method of claim 1 , wherein prior to collecting the particles in step (b) ...

Подробнее
21-11-2013 дата публикации

LONG-LASTING CONTROLLED-RELEASE LIPOSOME COMPOSITION AND METHOD FOR PRODUCING SAME

Номер: US20130309297A1
Принадлежит: TERUMO KABUSHIKI KAISHA

A liposome composition, which is obtained by mixing a water-miscible organic solution in which a phospholipid and cholesterol are contained in a total concentration of 100 to 200 w/v % in a water-miscible organic solvent with a first aqueous phase solution in an amount of 3/1 to 12/1 in terms of volume ratio to the water-miscible organic solution, thereby obtaining an emulsion in which the total concentration of the phospholipid and cholesterol in the resulting mixed phase is 15 to 50 w/v %, followed by subjecting the emulsion to external solution exchange with a second aqueous phase solution, wherein an ion gradient is formed between an aqueous phase in an internal region of a liposome membrane, including the first aqueous phase solution, and an aqueous phase in an external region of the liposome membrane, including the second aqueous phase solution, and a drug can be introduced in a high encapsulation amount. 1. A liposome composition obtained by mixing a water-miscible organic solution in which a phospholipid and cholesterol are contained in a total concentration of 100 to 200 w/v % in a water-miscible organic solvent with a first aqueous phase solution in an amount of 3/1 to 12/1 in terms of volume ratio to the water-miscible organic solution , thereby obtaining an emulsion in which the total concentration of the phospholipid and cholesterol in the resulting mixed phase is 15 to 50 w/v % , followed by subjecting the emulsion to external solution exchange with a second aqueous phase solution , wherein an ion gradient is formed between an aqueous phase in an internal region of a liposome membrane , the internal-region aqueous phase including the first aqueous phase solution , and an aqueous phase in an external region of the liposome membrane , the external-region aqueous phase including the second aqueous phase solution.2. The liposome composition according to claim 1 , wherein the ion gradient is pH proton gradient claim 1 , and the liposome composition has a pH ...

Подробнее
12-12-2013 дата публикации

Method of Making Small Liposomes

Номер: US20130330398A1
Принадлежит:

Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm. 125-. (canceled)26. A composition comprising liposomes of constrained particle size wherein at least about 90% of the liposomes are of a particle size less than about 200 nm and wherein the liposomes further comprise an adjuvant.27. A composition according to claim 26 , wherein the liposomes comprise phospholipids selected from the group consisting of dipalmitoylphosphatidylcholine (DPPC) claim 26 , phosphatidylcholine (PC; lecithin) claim 26 , phosphatidic acid (PA) claim 26 , phosphatidylglycerol (PG) claim 26 , phosphatidylethanolamine (PE) claim 26 , phosphatidylserine (PS). Other suitable phospholipids further include distearoylphosphatidylcholine (DSPC) claim 26 , dimyristoylphosphatidylcholine (DMPC) claim 26 , dipalmitoylphosphatidyglycerol (DPPG) claim 26 , distearoylphosphatidyglycerol (DSPG) claim 26 , dimyristoylphosphatidylglycerol (DMPG) claim 26 , dipalmitoylphosphatidic acid (DPPA); dimyristoylphosphatidic acid (DMPA) claim 26 , distearoylphosphatidic acid (DSPA) claim 26 , dipalmitoylphosphatidylserine (DPPS) claim 26 , dimyristoylphosphatidylserine (DMPS) claim 26 , distearoylphosphatidylserine (DSPS) claim 26 , dipalmitoylphosphatidyethanolamine (DPPE) claim 26 , dimyristoylphosphatidylethanolamine (DMPE) and distearoylphosphatidylethanolamine (DSPE).28. A composition according to claim 26 , wherein the liposomes comprise dipalmitoylphosphatidylcholine (DPPC).29. A composition according to claim 26 , ...

Подробнее
26-12-2013 дата публикации

SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS

Номер: US20130344132A1
Принадлежит: PACIRA PHARMACEUTICALS, INC.

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia. 1. A pharmaceutical composition comprising: at least one type of amphipathic lipid, and', 'at least one type of neutral lipid; and, 'a) a multivesicular liposome comprising'} 'polyhydroxy carboxylate salts and di- or tri-protic mineral salts of amide-type anesthetics,', 'b) an aqueous phase comprising'}wherein the aqueous phase is encapsulated within the multi vesicular liposome.2. The pharmaceutical composition of claim 1 , wherein the aqueous phase further comprises hydrochloric acid.3. The pharmaceutical composition of claim 1 , wherein the amphipathic lipid is provided in admixture with cholesterol claim 1 , plant sterols claim 1 , or combinations thereof.4. The pharmaceutical composition of claim 1 , wherein the di- or tri-protic mineral salts of the amide-type anesthetics are selected from the group consisting of sulfates claim 1 , phosphates claim 1 , and combinations thereof.5. The pharmaceutical composition of claim 1 , wherein the polyhydroxy carboxylate salts of the amide-type anesthetics are selected from the group consisting of glucuronate claim 1 , gluconate claim 1 , tartarate claim 1 , and combinations thereof.6. The pharmaceutical composition of claim 1 , wherein the amphipathic lipid is selected from the group consisting of phosphatidylcholines ...

Подробнее
06-02-2014 дата публикации

NOVEL NANOPARTICLES

Номер: US20140037741A1
Принадлежит: DSM IP ASSETS B.V.

Methods for the preparation of polymer-templated core-shell nanoparticles include the steps of (a) preparing a cationic polymeric core material comprising polymeric micelles, and (b) coating the core material with a silica-comprising shell by depositing the shell onto the polymeric micelles from at least one silica precursor to form the core-shell nanoparticles. Compositions which include the core-shell nanoparticles are adapted to facilitate controlled delivery of at least one active agent into a system in response to controlled changes in the pH of the system. 1. A method for the preparation of polymer-templated core-shell nanoparticles comprising the steps of:(a) preparing a cationic polymeric core material comprising polymeric micelles employing a quaternized polymer; and(b) coating said core material with a shell comprising silica by depositing the shell onto the polymeric micelles from at least one silica precursor to form the core-shell nanoparticles.2. The method as in claim 1 , wherein step (a) is practiced by preparing the polymeric core material by group transfer polymerisation or controlled radical polymerisation.3. The method of claim 1 , wherein the polymeric micelles comprise copolymeric micelles.4. The method of claim 3 , wherein the copolymeric micelles comprise a diblock copolymer micelle.5. The method of claim 4 , wherein said diblock copolymer micelle has a core comprising at least one block of a first polymer and a corona comprising at least one block of a second polymer wherein said second polymer is different to said first polymer.6. The method of or claim 4 , wherein said copolymer comprises a first polymer and a second polymer which both comprise amino-group comprising (alk)acrylate monomer units.7. The method of claim 6 , wherein said (alk)acrylate units comprise acrylate units.8. The method of claim 3 , wherein the copolymeric micelles are formed of a copolymer which comprises poly[2-(diisopropylamino)ethyl methacrylate)-block-2-( ...

Подробнее
13-02-2014 дата публикации

LIPOSOMAL APPARATUS AND MANUFACTURING METHODS

Номер: US20140044772A1
Принадлежит: Protiva Biotherapeutics, Inc.

The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol. 156-. (canceled)57. A process for producing a lipid vesicle encapsulating one or more therapeutic agents within the lipid vesicle , said process comprising:providing an aqueous solution in a first reservoir;providing an organic lipid solution in a second reservoir, wherein the lipids present in said organic lipid solution are solubilized in a lower alkanol at a concentration of about 75% v/v to 100% v/v, and wherein said aqueous solution and/or said organic lipid solution comprises one or more therapeutic agents; andmixing said organic lipid solution with said aqueous solution by introducing said organic lipid solution and said aqueous solution into a mixing environment at about equal flow rates;wherein said mixing instantaneously produces a lipid vesicle encapsulating said one or more therapeutic agents within the lipid vesicle by diluting said lower alkanol to a concentration of between 45% v/v to about 60% v/v; andwherein the mixing environment includes a mixing chamber, wherein said aqueous solution and said organic lipid solution are introduced into the mixing chamber at an angle of between about 27° and about 180° relative to each other and mixed within the mixing chamber.58. The process of claim 57 , further comprising diluting said lipid vesicle with a buffer solution wherein said lipid vesicle undergoes a continuous stepwise dilution to further stabilize the lipid vesicle.59. The process of claim 57 , wherein said one or more therapeutic agents is selected from the group consisting of a nucleic acid claim 57 , a hydrophilic active agent claim 57 , a hydrophobic active agent claim 57 , a small ...

Подробнее
13-02-2014 дата публикации

Liposome Composition

Номер: US20140044777A1
Принадлежит: Eisai R&D Management Co., Ltd.

The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture. 139-. (canceled)40. A pharmaceutical composition comprising:an amount of eribulin and/or a pharmaceutically acceptable salt thereof, said amount being contained in the internal phase of a liposome;{'sub': '4', 'sup': '+', 'wherein the internal phase of said liposome comprises citric acid and/or a citrate salt and at least one ammonium (NH) salt.'}41. The pharmaceutical composition according to claim 40 , wherein said at least one said ammonium (NH) salt is chosen from ammonium sulfate claim 40 , ammonium citrate claim 40 , and ammonium tartrate.42. The pharmaceutical composition according to claim 40 , wherein the internal phase further comprises at least one pH adjuster.43. The pharmaceutical composition according to claim 42 , wherein said at least one pH adjuster is chosen from a base.44. A method for preparing a pharmaceutical composition comprising eribulin and/or a pharmaceutically acceptable salt thereof comprising:{'sub': '4', 'sup': '+', '(a) preparing a liposome, wherein the internal phase of said liposome comprises citric acid and/or a citrate salt and at least one ammonium (NH) salt;'}(b) preparing a solution comprising eribulin and/or a pharmaceutically acceptable salt thereof; and(c) combining the liposome prepared in (a) with the solution prepared in (b) to obtain a liposome composition comprising eribulin and/or a pharmaceutically acceptable salt thereof entrapped in the internal phase of said liposome composition;wherein the entrapment achieved in (c) in said internal phase of said liposome composition results in an entrapment ratio of at least 60 to 100% of said eribulin and/or said pharmaceutically acceptable salt thereof.45. The method for preparing a pharmaceutical composition according to claim 44 , further comprising:(d) adjusting the pH of the external phase of said liposome to a value ...

Подробнее
27-02-2014 дата публикации

EFFICIENT METHOD FOR LOADING AMPHOTERIC LIPOSOMES WITH NUCLEIC ACID ACTIVE SUBSTANCES

Номер: US20140056970A1
Принадлежит: MARINA BIOTECH, INC.

A method for preparing amphoteric liposomes loaded with a polyanionic active agent as cargo, characterised by admixing an aqueous solution of said polyanionic active agent and an alcoholic solution of one or more amphiphiles and buffering said admixture to an acidic pH, said one or more amphiphiles being susceptible of forming amphoteric liposomes at said acidic pH, thereby to form such amphoteric liposomes in suspension encapsulating said active agent under conditions such that said liposomes form aggregates, and thereafter treating said suspension to dissociate said aggregates. Also disclosed are nucleic acid loaded amphoteric liposomes produced in accordance with the method, wherein said nucleic acids are oligonucleotides and said liposomes are multilamellar. 1. A method for preparing amphoteric liposomes loaded with a polyanionic active agent as cargo , characterised by admixing an aqueous solution of said polyanionic active agent and an alcoholic solution of one or more amphiphiles and buffering said admixture to an acidic pH , said one or more amphiphiles being susceptible of forming amphoteric liposomes at said acidic pH , thereby to form such amphoteric liposomes in suspension encapsulating said active agent under conditions such that said liposomes form aggregates , and thereafter treating said suspension to dissociate said aggregates.2. A method as claimed in claim 1 , wherein said acidic pH is at least one unit lower than the isoelectric point of said one or more of amphiphiles.3. A method as claimed in or claim 1 , wherein said alcoholic solution is buffered to an acidic pH using a buffer selected from acetate buffers claim 1 , formiate buffers claim 1 , glycine buffers claim 1 , maleic acid buffers claim 1 , phosphate buffers and citrate buffers or an acid selected from HCl claim 1 , acetic acid claim 1 , formic acid claim 1 , maleic acid claim 1 , sulfonic acid claim 1 , phosphoric acid and citric acid.4. A method as claimed in claim 1 , or claim 1 , ...

Подробнее
06-03-2014 дата публикации

Polymersomes, liposomes, and other species associated with fluidic droplets

Номер: US20140065234A1
Принадлежит: Harvard College

The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like.

Подробнее
20-03-2014 дата публикации

ENCAPSULATING LIPOSOMES

Номер: US20140079773A1
Принадлежит:

Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, and uses of liposomes encapsulating a biologically active agent to treat a subject. 1. A composition comprising liposomes , sulfate ions , and hydrogen ions , wherein the concentration of the hydrogen ions inside the liposomes is greater than the concentration of the hydrogen ions outside the liposomes.2. The composition of comprising sulfuric acid.3. The composition of claim 1 , wherein the interior of said liposomes has a pH of at least 3 pH units lower than the exterior of said liposomes.4. The composition of comprising a bioactive agent in the interior of the liposomes.5. The composition of wherein said bioactive agent is an analgesic.6. The composition of wherein said bioactive agent is an opioid.7. The composition of wherein said bioactive agent is selected from the group consisting of hydromorphone claim 4 , chloroquine claim 4 , and buprenorphine.8. The composition of wherein said bioactive agent is an antibiotic.9. The composition of claim 8 , wherein said antibiotic is doxycycline.10. The composition of wherein the bioactive agent is selected from the group consisting of an antitumor agent claim 4 , an anaesthetic claim 4 , an analgesic claim 4 , an antimicrobial agent claim 4 , a hormone claim 4 , an antiasthmatic agent claim 4 , a cardiac glycoside claim 4 , an antihypertensive claim 4 , a vaccine claim 4 , an antiarrhythmic claim 4 , an immunomodulator claim 4 , a steroid claim 4 , a monoclonal antibody claim 4 , a neurotransmitter claim 4 , a radionuclide claim 4 , a radio contrast agent claim 4 , a nucleic acid claim 4 , a protein claim 4 , a herbicide claim 4 , a pesticide claim 4 , and suitable combinations thereof.11. The composition of comprising an aqueous buffer and a base outside the liposomes.12. The ...

Подробнее
03-04-2014 дата публикации

Multilayer Biodegradable Microparticles for Sustained Release of Therapeutic Agents

Номер: US20140093552A1
Принадлежит: SKS Ocular, LLC

Microparticles are prepared by a method that includes: (a) forming a layer comprising a first polymer on a solid surface by depositing a first composition one or more times on the solid surface, wherein the first composition comprises the first polymer and a first solvent, and evaporating the first solvent in the first composition; (b) forming one or more layers comprising a second polymer and a therapeutic agent by depositing a second composition on all or part of the layer formed in step (a), wherein the second composition comprises the second polymer, the therapeutic agent, and a second solvent; and evaporating the second solvent in the second composition; and (c) forming an additional layer comprising a third polymer by depositing a third composition one or more times on a previously formed layer, wherein the third composition comprises the third polymer and a third solvent; and evaporating the third solvent in the third composition. 1. A method for preparing a multilayer microparticle , the method comprising(a) forming a layer comprising a first polymer on a solid surface by depositing a first composition one or more times on the solid surface, wherein the first composition comprises the first polymer and a first solvent, and evaporating the first solvent in the deposited first composition;(b) forming a layer comprising a second polymer and a therapeutic agent by depositing a second composition on all or part of the layer formed in step (a), wherein the second composition comprises the second polymer, the therapeutic agent, and a second solvent; and evaporating the second solvent in the deposited second composition; and(c) forming an additional layer comprising a third polymer by depositing a third composition one or more times on a previously formed layer, wherein the third composition comprises the third polymer and a third solvent; and evaporating the third solvent in the deposited third composition.2. The method of claim 1 , wherein the first and the third ...

Подробнее
03-04-2014 дата публикации

METHOD FOR THE DELIVERY OF MOLECULES LYOPHILIZED ONTO MICROPARTICLES TO PLANT TISSUES

Номер: US20140096284A1
Принадлежит:

The invention provides particles and methods to deliver freeze- or air-dried molecules to cells. 1. A plurality of particles for biolistics of about 0.3 μm to about 1.2 μm in diameter having a freeze-dried or air-dried coating of at least one isolated molecule.2. The plurality of particles of wherein the at least one the isolated molecule includes isolated protein.3. The plurality of particles of wherein the isolated molecule includes isolated nucleic acid and isolated protein.4. The plurality of particles of wherein the isolated molecule includes a drug.5. A method to deliver particles for biolistic delivery of at least one molecule comprising:a) providing a substrate having a solution with a mixture of a plurality of particles and at least one isolated molecule;b) freeze-drying or air-drying the solution in or on the substrate to provide a preparation of particles coated with the at least one molecule; andc) biolistically delivering the plurality to eukaryotic cells in an amount effective to deliver the at least one molecule into the cells, wherein if the cells are not plant cells, the particles are about 0.3 μm to about 1.2 μm in diameter.6. The method of wherein the particles are about 0.3 μm to about 1.2 μm in diameter.7. The method of wherein the molecule is not isolated ribonucleic acid.8. The method of wherein the cells are plant cells.9. The method of wherein the at least one molecule is a protein or a peptide.10. The method of wherein the protein is a recombinase claim 9 , an endonuclease or an enzyme that otherwise modifies nucleic acid.11. The method of wherein the molecule is a DNA ligase claim 10 , polymerase claim 10 , restriction enzyme claim 10 , recombinase claim 10 , such as Cre claim 10 , FLP claim 10 , R or Gin claim 10 , or a nuclease such as a zinc finger nuclease or a transcription activator effector nuclease.12. The method of wherein the particles are coated with isolated nucleic acid and isolated protein.13. The method of wherein the cells ...

Подробнее
06-01-2022 дата публикации

Method of encapsulating active ingredients in liposomes

Номер: US20220000781A9
Принадлежит: ABNOBA GmbH

A method for encapsulating active ingredients in liposomes having an active ingredient solution encapsulated with a bilayer composed of two monomolecular layers of amphiphilic compounds comprises:(a) providing the active ingredient solution;(b) providing an emulsion by emulsifying the active ingredient solution in a first liquid in the presence of the amphiphilic compound;(c) providing a liquid phase;(d) contacting the emulsion with the liquid phase to form a phase boundary; and(e) centrifuging the emulsion and the liquid phase that are in contact with one another via the phase boundary, wherein, on passage of the phase boundary, the amphiphilic compound enriched there is added onto the monomolecular inner layer to form a monomolecular outer layer, in order to create the bilayer.The first liquid of the emulsion is chosen such that the solubility of the amphiphilic compound in the first liquid is not more than 1×10−4 mol/l.

Подробнее
05-01-2017 дата публикации

RECEPTOR-TARGETED NANOPARTICLES FOR ENHANCED TRANSCYTOSIS MEDIATED DRUG DELIVERY

Номер: US20170000899A1
Принадлежит:

Receptor-targeted nanoparticles (R-NPs) are provided for selective transport into and through targeted tissues of therapeutic, prophylactic and diagnostic agents. R-NPs can include polymeric particle, lipid particles, inorganic particles, or a combination thereof with a targeting moiety selective for binding to a receptor on the cells where the agent is to be delivered, where the receptor mediates transcytosis of the nanoparticle into and through the cells. In a preferred embodiment, the targeting moiety is the neonatal Fc receptor. Examples demonstrate Fc-targeted nanoparticles which are actively transported across the intestinal epithelium, providing a route for the oral delivery of nanoparticle encapsulated active agents including peptides such as insulin. 1. A nanoparticle formulation for transport of agents through tissue , tissue barriers , and tissue linings comprising an effective amount of nanoparticles comprisinga polymeric, lipid or inorganic core comprising a therapeutic, prophylactic, or diagnostic agent, andtargeting moieties that bind to a receptor on the surface of the cells in the tissue to effect transcytosis of the nanoparticles into and through the cells, wherein the targeting moieties are bound to the surface of the nanoparticles.2. The nanoparticle formulation of for delivery into and through heart claim 1 , skeletal muscle claim 1 , or adipose tissue claim 1 , wherein the receptors are selected from the group consisting of gp60 and ligands for FcRn.3. The nanoparticle formulation of for delivery into and through testis tissue claim 1 , wherein the receptors are selected from the group consisting of chorionic gonadotropin receptor claim 1 , Insulin receptor and insulin-like growth factor receptor claim 1 , FcRn claim 1 , and Transferrin receptor.4. The nanoparticle formulation of for delivery into and through brain tissue claim 1 , wherein the receptors are selected from the group consisting of insulin receptor; insulin-like growth factor ...

Подробнее
07-01-2021 дата публикации

SYSTEM AND METHOD FOR MAKING MICROSPHERES AND EMULSIONS

Номер: US20210001290A1
Принадлежит: OAKWOOD LABORATORIES, LLC

Various examples of systems and methods for making microspheres, microparticles, and emulsions are provided. In one example, a system and method for forming microspheres comprises: pumping a dispersed phase liquid and a continuous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase liquid and continuous phase liquid to a high shear environment within the impeller pump's pump chamber. In another example, a system and method for forming an emulsion comprises: pumping a dispersed phase liquid and an inner aqueous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase and the inner aqueous phase to a high shear environment within the impeller pump's pump chamber. 1. A system for forming microspheres , comprising: a dispersed phase input fitting at a first end,', 'a needle tube at a second end, and', 'a dispersed phase output fitting oriented between the dispersed phase input fitting and the needle tube,', 'wherein the dispersed phase needle has a hollow bore;, 'a dispersed phase needle including a plurality of tubes,', 'a tee input fitting or a wye input fitting,', 'a continuous phase input fitting, and', 'a continuous phase output fitting,', 'wherein the tubes each include a hollow bore; and, 'a tee or a wye including an input tube having an input fitting and a hollow bore,', 'a housing,', 'an output tube having an output fitting and a hollow bore,', 'a hollow interior, and', 'wherein the impeller includes a plurality of impeller blades and a base, wherein the base includes a magnet to magnetically engage a rotating magnetic field outside of the pump chamber, and wherein the impeller rotates and creates a direction of natural flow of a fluid through the pump chamber in a direction from the output tube toward the input tube.', 'an impeller is oriented within the hollow interior,'}], 'a pump chamber including2. The system of claim 1 , wherein the dispersed phase needle output fitting engages the tee input ...

Подробнее
07-01-2016 дата публикации

APPARATUS AND METHODS FOR MAKING VESICLES

Номер: US20160001290A1
Автор: Issadore David, Ko Jin A.

A microfluidic device includes a substrate and a microfluidic channel embedded in the substrate. The microfluidic channel includes a plurality of fluid inlets, at least one waste outlet, at least one vesicle outlet, a flow junction joining the at least one vesicle outlet and the at least one waste outlet in fluid communication, the flow junction having a fluid flow path that is orthogonal to the plane of the substrate, and at least one membrane between the at least one vesicle outlet and the at least one waste outlet configured to intercept a portion of the fluid flow path. 1. A microfluidic device for generating vesicles comprising:a substrate; and a plurality of fluid inlets;', 'at least one waste outlet;', 'at least one vesicle outlet;, 'a microfluidic channel embedded in the substrate, the microfluidic channel includingto a flow junction joining the at least one vesicle outlet and the at least one waste outlet in fluid communication, the flow junction having a fluid flow path that is orthogonal to the plane of the substrate; andat least one membrane between the at least one vesicle outlet and the at least one waste outlet configured to intercept a portion of the fluid flow path.2. The microfluidic device of claim 1 , wherein the substrate is comprised of a polymer.3. The microfluidic device of claim 2 , wherein the substrate is comprised of polydimethylsiloxane.4. The microfluidic device of claim 1 , wherein the plurality of fluid inlets comprises a fluid inlet for a liquid and a fluid inlet for an emulsion.5. The microfluidic device of claim 4 , wherein the emulsion comprises a plurality of water-in-oil emulsion droplets.6. The microfluidic device of further comprising at least one emulsion droplet generator in fluid communication with the emulsion inlet.7. The microfluidic device of claim 1 , wherein the at least one membrane is a nanoporous membrane.8. The microfluidic device of claim 7 , wherein the nanoporous membrane is selected from the group consisting ...

Подробнее
03-01-2019 дата публикации

AEROGELS, MATERIALS USING SAME, AND METHODS FOR PRODUCING SAME

Номер: US20190001293A1
Принадлежит:

Disclosed is an aerogel, having, on the surface of the aerogel, at least one type of dialkyldisiloxane bond serving as a hydrophobic group, and/or at least one type of crosslinked disiloxane bond serving as a hydrophobic group. Further disclosed is a material serving as at least one material selected from among a heat-insulation material, a sound-absorbing material, a water-repellant material, and an adsorption material, and this material includes the above-mentioned aerogel. Yet further disclosed is a method for producing the above-mentioned aerogel. 1. An aerogel comprising:a first aerogel having, on a surface of the first aerogel, at least one type of dialkyldisiloxane bond serving as a hydrophobic group; anda second aerogel having on a surface of the second aerogel one type of trialkylsiloxane bond.2. The aerogel according to claim 1 , wherein the alkyl groups present in the one type of dialkyldisiloxane bond each have a carbon number from 1 to 10.3. An aerogel claim 1 , according to claim 1 ,wherein the number of molecules of the first aerogel is about 0.5 to about 1.5 times greater than the number of molecules of the second aerogel.4. The aerogel according to claim 1 , wherein the alkyl groups present in the at least one type of trialkylsiloxane bond each have a carbon number from 1 to 10.5. (canceled)6. An aerogel claim 1 , comprising:an third aerogel having, on a surface of said third aerogel, at least one type of dialkyldisiloxane bond serving as a hydrophobic group, and/or at least one type of crosslinked disiloxane bond serving as a hydrophobic group; anda fourth aerogel having on a surface of said fourth aerogel at least one type of trialkylsiloxane serving as a hydrophobic group, wherein the number of molecules of the third aerogel is about 0.5 to about 1.5 times greater than the number of molecules of the fourth aerogel.7. The aerogel according to claim 6 , wherein the alkyl groups present in the at least one type of trialkylsiloxane bond each have a ...

Подробнее
03-01-2019 дата публикации

Method for Producing Colloidosome Microcapsules

Номер: US20190001294A1
Принадлежит:

This invention relates to a process for colloidosome-type microcapsules elaboration from solid particles microcapsules obtained by ionic gelation. In the process, an (O/W) type emulsion is initially generated stabilized with the solid particles microcapsules, and then the particles are fixed to the interface by adsorption of polyelectrolytes, cross-linking, heat treatment or fatty coating, generating the colloidosome with the water-insoluble phase encapsulated in the core and covered by the shell particles. 1) A process for elaborating colloidosomes-type microcapsules comprising:a) dispersing in water agglomerates of solid particles microcapsules obtained by ionic gelation to form a suspension;b) emulsify a liquid insoluble in water using as emulsifier the suspension obtained in a); andc) fix the solids adsorbed on the water-liquid interface insoluble in water, to obtain the colloidosomes.2) A process according to claim 1 , wherein the mixture obtained in c) is dried to obtain powder colloidosomes.3) A process according to claim 1 , wherein the microcapsules of step a) comprise water-insoluble solids selected from the group consisting of metallic and non-metallic minerals claim 1 , phyllosilicates claim 1 , polymer particles and insoluble solids obtained via synthesis claim 1 , extraction or by bioprocesses.4) A process according to claim 1 , wherein the solid particles microcapsules of step a) have a size between 10 nm and 1000 μm.5) A process according to claim 1 , wherein in step a) shear-type disruptive forces claim 1 , cavitation claim 1 , shock claim 1 , pressure drop or combinations thereof are applied to prevent the agglomerates formation.6) A process according to claim 1 , wherein the fixation of the adsorbed particles on the water-liquid interface water-insoluble of step c) is carried out by polyelectrolytes adsorption claim 1 , cross-linking claim 1 , heat treatment and/or treatment with a fatty acid emulsion or fatty acids mixture.7) A process according ...

Подробнее
07-01-2021 дата публикации

MICROSPHERE-BASED INSULATING MATERIALS FOR USE IN VACUUM INSULATED STRUCTURES

Номер: US20210002162A1
Принадлежит: WHIRLPOOL CORPORATION

A low-density insulating material for use in a vacuum insulated structure for an appliance includes a plurality of microspheres that includes a plurality of leached microspheres. Each leached microsphere has an outer wall and an interior volume. The outer wall has a hole that extends through the outer wall and to the interior volume. A binder engages outer surfaces of the plurality of leached microspheres, wherein the binder cooperates with the plurality of leached microspheres to form at least one microsphere aggregate. The interior volume of each leached microsphere defines an insulating space that includes an insulating gas. The insulating space of each leached microsphere is at least partially defined by the binder. 147-. (canceled)48. A low-density insulating material for use in a vacuum insulated structure for an appliance , the low-density insulating material comprising:a plurality of microspheres that includes a plurality of leached microspheres, each leached microsphere having an outer wall and an interior volume, wherein the outer wall has a hole that extends through the outer wall and to the interior volume; and the interior volume of each leached microsphere defines an insulating space that includes an insulating gas; and', 'the insulating space of each leached microsphere is at least partially defined by the binder., 'a binder that engages outer surfaces of the plurality of leached microspheres, wherein the binder cooperates with the plurality of leached microspheres to form at least one microsphere aggregate; wherein'}49. The low-density insulating material of claim 48 , wherein the binder engages the outer surface of each leached microsphere claim 48 , wherein the binder is disposed within a portion of the holes of the plurality of leached microspheres.50. The low-density insulating material of claim 48 , wherein the insulating gas includes at least one of carbon dioxide claim 48 , argon claim 48 , xenon claim 48 , krypton and neon.51. The low-density ...

Подробнее
04-01-2018 дата публикации

METHOD OF PREPARING HYDROPHOBIC METAL OXIDE-SILICA COMPOSITE AEROGEL AND HYDROPHOBIC METAL OXIDE-SILICA COMPOSITE AEROGEL PREPARED THEREBY

Номер: US20180002182A1
Принадлежит:

The present invention relates to a method of preparing a hydrophobic metal oxide-silica composite aerogel having a high specific surface area and a low tap density and a hydrophobic metal oxide-silica composite aerogel prepared thereby. Thus, the preparation method may not only have excellent productivity and economic efficiency due to a relatively simpler preparation process and shorter preparation time than the related art, but may also prepare a hydrophobic metal oxide-silica composite aerogel having a high specific surface area and a low tap density. 1. A method of preparing a hydrophobic metal oxide-silica composite aerogel , the method comprising steps of:(1) adding a metal ion solution and an acid catalyst to a water glass solution and mixing together to prepare a metal oxide-silica composite gel;(2) surface-modifying the metal oxide-silica composite gel to prepare a hydrophobic metal oxide-silica composite wet gel; and(3) drying the hydrophobic metal oxide-silica composite wet gel,wherein the method further comprises treating the metal oxide-silica composite gel with alcohol before the surface modification of step 2.2. The method of claim 1 , wherein a concentration of water glass in the water glass solution is in a range of 0.1 M to 2.0 M.3. The method of claim 1 , wherein a concentration of metal ions in the metal ion solution is in a range of 0.05 M to 2.0 M.4. The method of claim 1 , wherein the metal ion solution is a binary metal ion solution including calcium ions (Ca) and magnesium ions (Mg).5. The method of claim 4 , wherein a molar ratio of the calcium ion (Ca) to the magnesium ion (Mg) in the metal ion solution is in a range of 1:0.3 to 1:3.6. The method of claim 1 , wherein the metal ion solution is added in an amount such that a molar ratio of metal ions to water glass is in a range of 0.5 to 1.7. The method of claim 1 , wherein step 1 is performed at a pH of 6 to 8.8. The method of claim 1 , wherein the acid catalyst comprises at least one ...

Подробнее
13-01-2022 дата публикации

METHOD FOR PRODUCING AEROGELS AND AEROGELS OBTAINED USING SAID METHOD

Номер: US20220009786A1
Принадлежит:

The invention relates to a method for producing an aerogel under increased pressure, to the aerogel obtained using said method and to their use. 1. A method for producing a silica aerogel by means of a sol-gel process , comprisingproducing a lyogel from a sol; andconverting the lyogel into an aerogel, whereinthe production of the lyogel is carried out at least partially at a pressure of more than 30 bar.2. The method according to claim 1 , wherein the production of the lyogel is carried out in a compressed gas claim 1 , a supercritical substance claim 1 , or a mixture of both.3. The method according to claim 1 , wherein:the pressure is selected from more than 40 bar, more than 50 bar, more than 60 bar, more than 70 bar, and more than 74 bar; and/orthe production of the lyogel is carried out at a temperature selected from above 50° C., 60° C., 70° C., and 80° C.4. The method according to claim 1 , wherein converting the lyogel into an aerogel is carried out at a pressure of more than 50 bar.5. The method according to claim 1 , wherein the sol is a solution or a dispersion of a precursor.6. The method according to claim 5 , wherein the precursor is selected from silicic acids claim 5 , in particular colloidal silicic acid claim 5 , colloidal silica claim 5 , silanes claim 5 , silica sols claim 5 , tetraalkoxysilanes claim 5 , siloxanes and mixtures thereof.7. The method according to claim 1 , wherein the sol comprises a hydrophobing silanizing agent.8. The method according to claim 1 , wherein the production of the lyogel is carried out by introducing the sol into a pressurized apparatus in the form of droplets.9. The method according to claim 1 , wherein after the production of the lyogel a solvent exchange is performed.10. The method according to claim 9 , wherein the solvent exchange occurs by contacting the lyogel with an organic solvent at elevated pressure.11. The method according to claim 10 , wherein the organic solvent is brought into contact with the lyogel ...

Подробнее
20-01-2022 дата публикации

SEMICONDUCTOR NANOPARTICLES AND METHOD OF PRODUCING SEMICONDUCTOR NANOPARTICLES

Номер: US20220017819A1
Принадлежит:

A semiconductor nanoparticle includes a core and a shell covering a surface of the core. The shell has a larger bandgap energy than the core and is in heterojunction with the core. The semiconductor nanoparticle emits light when irradiated with light. The core is made of a semiconductor that contains M, M, and Z. Mis at least one element selected from the group consisting of Ag, Cu, and Au. Mis at least one element selected from the group consisting of Al, Ga, In and Tl. Z is at least one element selected from the group consisting of S, Se, and Te. The shell is made of a semiconductor that consists essentially of a Group 13 element and a Group 16 element. 1. A semiconductor nanoparticle comprising:a core comprising a semiconductor being adapted to emit photoluminescence upon being irradiated with light; anda shell covering a surface of the core and having a bandgap energy larger than a bandgap energy of the core, the shell being in heterojunction with the core,{'sup': 1', '2', '1, 'claim-text': [{'sup': '2', 'Mis at least one element selected from the group consisting of Al, Ga, In, and Tl, and comprises at least In,'}, 'and Z is at least one element selected from the group consisting of S, Se, and Te, and comprises at least S,, 'wherein the semiconductor contains M, M, and Z, wherein Mis at least one element selected from the group consisting of Ag, Cu, and Au, and comprises at least Ag,'}wherein the shell comprises a semiconductor containing a Group 13 element and a Group 16 element, andwherein a photoluminescence lifetime of the semiconductor nanoparticles is 200 ns or less.2. The semiconductor nanoparticle according to claim 1 , wherein the shell contains In as the Group 13 element.3. The semiconductor nanoparticle according to claim 2 , wherein the shell contains S as the Group 16 element.4. The semiconductor nanoparticle according to claim 1 , wherein the shell contains Ga as the Group 13 element.5. The semiconductor nanoparticle according to claim 4 , wherein ...

Подробнее
12-01-2017 дата публикации

MICROPARTICLES WITH EFFICIENT BIOACTIVE MOLECULE INCORPORATION

Номер: US20170007546A1
Принадлежит:

The present invention relates to, drug-filled polymeric microparticles comprising a gas core and shell that combine high incorporation efficiency for hydrophilic and/or hydrophobic drugs with a large, preferably hollow, core. 1. A polymer microparticle with a microparticle size ranging between 0.5 and 5 μm comprising a biologically active agent prepared by:a) providing a first emulsion (A) by mixing an organic solvent (1), a biodegradable polyester, and an organic non-solvent for the polymer (2), wherein the ratio of biodegradable polyester/organic non-solvent (2) is 1:10 to 1:1% w/w, and adding to this mixture up to 40% v/v of an aqueous solution and wherein a biologically active agent is added to the organic mixture and or aqueous solution;b) preparing a second emulsion (B) by adding to this first emulsion (A) excess of an aqueous solution;c) applying conditions for volatizing the organic solvent (1);d) applying conditions for removal of water; ande) applying conditions for removal of the non-solvent (2).2. A polymer microparticle according to claim 1 , wherein the biodegradable polyester has a molecular weight between 1.000 and 200.000 g/mol.3. A polymer microparticle according to claim 1 , wherein the the ratio biodegradable polyester/organic non solvent (2) is 1:8 to 1:34. A polymer microparticle according to claim 1 , wherein a non solvent (3) that is not removed in step e) is added to step a).5. A polymer microparticle according to wherein the polymer is selected from the group comprising polylactide either in the L or DL form claim 1 , poly-lactide-co-glycolide claim 1 , polycaprolacton claim 1 , a combination thereof claim 1 , or a block co-polymer thereof.6. A polymer microparticle according to claim 5 , wherein the polymer comprises at least one moiety modified with at least one hydrophobic group that is preferably selected from the group comprising fluoride claim 5 , alkyl chain comprising from 6 to 24 carbon atoms or a combination of these.7. A polymer ...

Подробнее
10-01-2019 дата публикации

MICROENCAPSULATION OF B-ALANINE

Номер: US20190008786A1
Принадлежит: Innobio Corporation Limited

Microencapsulation of β-alanine uses β-alanine as a core material and a mixture of a wall material and an additive as a release material. The additive comprises: a fatty acid-based saturated or unsaturated fatty acid glyceride containing 12-22 carbon atoms and a phospholipid. The fatty acid glyceride is a mono-fatty acid glyceride or a di-fatty acid glyceride, or a mixture formed by mixing the mono-fatty acid glyceride and the di-fatty acid glyceride at arbitrary proportions. The microencapsulation technique solves problems occurring with the use of β-alanine as a raw material, such as high moisture absorption tendency thereof, unpleasant smell and stinging accompanying administration of the same. The invention selects and combines the wall material and the additive to attain a balance between embedment and release with respect to a microencapsulated β-alanine product, and effectively optimizes release kinetics of the product, thereby enabling a stable release of the product, and realizing effective embedment and uniform release. Therefore, the microencapsulated β-alanine is applicable to the preparation of food, drugs, health-enhancing products and functional food. 1. A microencapsulated β-alanine using β-alanine as a core material and a mixture of a wall material and an additive as a release material , wherein the additive comprises a fatty acid-based saturated or unsaturated fatty glyceride containing 12 to 22 carbon atoms and a phospholipid; and the fatty glyceride is a monoglyceride , a diglyceride , or a mixture thereof in any ratio.2. The microencapsulated β-alanine according to claim 1 , wherein the fatty glyceride is selected from the fatty acid-based fatty glyceride containing 16 to 18 carbon atoms.3. The microencapsulated β-alanine according to claim 2 , wherein the fatty glyceride comprises any one of the followings: glyceryl hexadecanoate claim 2 , glyceryl hexadecenoate claim 2 , glyceryl octadecanoate claim 2 , glycerol octadecenoate claim 2 , ...

Подробнее
10-01-2019 дата публикации

PROCESS FOR ENCAPSULATING SOLUBLE BIOLOGICS, THERAPEUTICS, AND IMAGING AGENTS

Номер: US20190008788A1
Принадлежит: THE TRUSTEES OF PRINCETON UNIVERSITY

An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described. The aggregation of these nanoparticles to form larger microparticles and monoliths provides a highly loaded construct (e.g., a depot) for the sustained and controlled release of actives. 1. A method for encapsulating a water soluble agent comprising:making an inverse nanoparticle dispersion by dissolving the water soluble agent in a first polar process solvent to form a water soluble agent solution,dissolving a copolymer in a second polar process solvent to form a copolymer solution,continuously mixing the water soluble agent solution and the copolymer solution with a nonprocess solvent to form a mixed solution from which inverse nanoparticles assemble to form an inverse nanoparticle dispersion, andaggregating the inverse nanoparticles to form microparticles or larger constructs to encapsulate the water soluble agent,wherein the copolymer comprises at least one region that is more polar and at least one region that is less polar,wherein the nonprocess solvent is less polar than the first polar process solvent,wherein the nonprocess solvent is less polar than the second polar process solvent,wherein the inverse nanoparticle comprises a core and a shell,wherein the core comprises the more polar region of the copolymer and the water soluble agent,wherein the shell comprises the less polar region of the copolymer, andwherein the mixing causes no more than 20 percent by volume of the first polar process solvent and the second polar process solvent to phase separate from the mixed solution.2. The method of claim 1 , wherein the water soluble agent is selected from the group consisting of a biologic material claim 1 , an amino acid claim 1 , a peptide claim 1 , a protein claim 1 , an antibody claim 1 , DNA claim 1 , RNA claim 1 , mRNA claim 1 , siRNA claim 1 , a saccharide claim 1 , glutathione claim ...

Подробнее
12-01-2017 дата публикации

METHOD FOR PRODUCING A FUSION MIXTURE FOR TRANSFER OF A CHARGED MOLECULE INTO AND/OR THROUGH A LIPID MEMBRANE

Номер: US20170009255A1
Принадлежит:

A method for producing a fusion mixture for a transfer of a charged molecule into and/or through a lipid membrane is disclosed. In an embodiment, the method comprises: providing an initial mixture comprising a positively charged amphipathic molecule A, an aromatic molecule B with hydrophobic range and a neutral, amphipathic molecule C, whereby the molecule types are at hand in a ratio A:B:C of 1-2:0.02-1:0-1 mol/mol; generating a fusogenic liposome by absorption of the initial mixture in a watery solvent; providing a charged molecule; forming a complex from the charged molecule and a neutralizing agent; and incubating the complex with the fusogenic liposome so that a fusion mixture is obtained. 117.-. (canceled)18. A method for producing a fusion mixture for a transfer of a charged molecule into and/or through a lipid membrane comprising:a) providing an initial mixture comprising a positively charged amphipathic molecule A, an aromatic molecule B with hydrophobic range and a neutral, amphipathic molecule C, whereby the molecule types are at hand in a ratio A:B:C of 1-2:0.02-1:0-1 mol/mol,b) generating a fusogenic liposome by absorption of the initial mixture in a watery solvent,c) providing a charged molecule,d) forming a complex from the charged molecule and a neutralizing agent, ande) incubating the complex with the fusogenic liposome so that a fusion mixture is obtained.19. The method according to claim 18 , wherein step d) occurs in a manner that the complex has a zeta potential of −50 mV to 0 mV.20. The method according to claim 18 , wherein before step e) an adding of cations occurs in order to stabilize the complex.21. The method according to claim 20 , wherein the cations are added with a concentration of 0 to 1 mM.22. The method according to claim 18 , wherein step d) comprises an adding of albumin.23. The method according to claim 18 , wherein before claim 18 , during and/or after step e) a lipid membrane destabilizing agent is added.24. The method ...

Подробнее
27-01-2022 дата публикации

Coacervation process to encapsulate organic pigments that show improved weather fastness

Номер: US20220025186A1
Принадлежит: COLORANTS INTERNATIONAL LTD

In a first aspect, the present invention relates to an encapsulated organic pigment comprising of an organic pigment as core material and a material capable of forming microcapsules as shell material, wherein the particle size of the encapsulated pigment (core-shell-product) is in the range from 50 nm to 500 μm and the particle size distribution D 90 is <100 μm.

Подробнее
11-01-2018 дата публикации

MICROCAPSULES HAVING DUAL REAGENTS SEPARATED BY THE CAPSULE WALL AND METHODS FOR MAKING SAME

Номер: US20180010013A1
Принадлежит:

Ruptureable, dual reagent mono-capsules are disclosed that have a core composition, which includes a first reagent, encapsulated within a polymer wall, and a shell connected to an exterior surface of the polymer wall by a surfactant. The shell is made from a second reagent that is chemically bonded to the surfactant by a chemical electrostatic interaction. Upon rupture of the polymer wall of the mono-capsule, the first reagent and the second reagent chemically react with one another to form a reaction product. 1. A ruptureable capsule comprising:a core composition encapsulated within a polymer wall, the core composition comprising a first reagent; anda shell connected to an exterior surface of the polymer wall by a surfactant, the shell comprising a second reagent attracted to the surfactant by a chemical electrostatic interaction;wherein, upon rupture of the polymer wall, the first reagent and the second reagent chemically react with one another to form a reaction product.2. The capsule of claim 1 , wherein the reaction product seals the rupture in the capsule or seals a feature of a surface upon which the capsules are disposed.3. The capsule of claim 1 , wherein the second reagent comprises a mineral containing a metal that is available for chemical attraction or bonding to the surfactant claim 1 , and the first reagent is a carboxylic acid.4. The capsule of claim 3 , wherein the metal is selected from the group consisting of aluminum calcium claim 3 , silver claim 3 , magnesium claim 3 , iron claim 3 , copper claim 3 , and cobalt claim 3 , and combinations thereof.5. The capsule of claim 3 , wherein the metal is an aluminum.6. The capsules of claim 1 , wherein the second reagent is an inorganic compound and the shell connected to the exterior surface of the polymer wall by the surfactant is crystalline.7. The capsule of claim 6 , wherein the core composition comprises a natural oil claim 6 , and the inorganic compound catalyzes a reaction of the natural oil.8. ...

Подробнее
10-01-2019 дата публикации

COMPOSITION, METHOD OF MAKING COMPOSITION, AND ARTICLE

Номер: US20190010341A1
Принадлежит:

A composition having pH of 5 or less comprises composite particles dispersed in an aqueous continuous liquid phase. Each composite particle comprises a polymer core surrounded by a silicaceous shell. From 3 to 50 percent of silicon atoms in the silicaceous shells are bonded to respective organic groups via a silicon-carbon covalent bond. The weight ratio of the total amount of the silica in the composition to the total amount of the at least one polymer is from 0.1 to 19. The composition is useful for making various articles. A method for making the composition is also disclosed. Silicaceous particles dispersed in an aqueous phase, wherein from 3 to 50 percent of silicon atoms in the silicaceous particles are bonded to organic groups via a silicon-carbon covalent bond are also disclosed. 120-. (canceled)21. A composition comprising:an aqueous continuous liquid phase; a polymer core comprising at least one polymer,', 'a silicaceous shell surrounding and disposed on the polymer core, wherein from 3 to 50 percent of silicon atoms in the silicaceous shell are bonded to respective organic groups via a silicon-carbon covalent bond, and wherein the weight ratio of a total amount of the silica in the composition to the total amount of the at least one polymer is from 0.1 to 19, and, 'composite particles dispersed in the aqueous continuous liquid phase, each composite particle comprisingwherein the composition has a pH of 5 or less.22. The composition of claim 21 , wherein the organic groups comprise at least one of an alkyl group having from 1 to 4 carbon atoms claim 21 , a chloromethyl group claim 21 , an epoxyalkyl group having from 1 to 6 carbon atoms claim 21 , an epoxyalkyleneoxyalkyl group having from 1 to 6 carbon atoms claim 21 , an alkenyl group having from 1 to 6 carbon atoms claim 21 , and a combination thereof.23. The composition of claim 21 , wherein the composition further comprises a water-soluble polymer.24. The composition of claim 21 , wherein the water- ...

Подробнее
10-01-2019 дата публикации

ORGANIC RARE EARTH SOLID MICELLE, PREPARATION METHOD THEREFOR, AND METHOD FOR INCREASING PHOTOELECTRIC CONVERSION EFFICIENCY OF SOLAR BATTERY

Номер: US20190010389A1
Принадлежит: QINGDAO UNIVERSITY

Provided are an organic rare-earth solid micelle, a preparation method therefor, and a method for increasing the photoelectric conversion efficiency of a solar battery. A small organic conjugated ligand is taken as a first ligand, an amphiphilic diblock polymer is taken as a second ligand, and the first ligand and the second ligand are mixed and doped with a rare-earth chloride solution, and self-assembled to form an organic rare-earth solid micelle, whereby the fluorescence emission intensity and the fluorescence efficiency of the rare-earth element are improved. Next, the prepared organic rare-earth solid micelle is spin coated on an ITO layer of a solar battery, to prepare a solar battery with the organic rare-earth solid micelle. Therefore the sunlight absorption of a cell is increased, and the photoelectric conversion efficiency is improved. The preparation process is simple, low in cost, high in photoelectric conversion efficiency, and environmentally friendly. 1. A method for preparing an organic rare-earth solid micelle , comprising: taking a small organic conjugated ligand as a first ligand and an amphiphilic diblock polymer as a second ligand , mixing and doping the first ligand and the second ligand with a rare-earth chloride solution , and self-assembling to form an organic rare-earth solid micelle;wherein the amphiphilic diblock polymer is polymethyl methacrylate-b-polyacrylic acid (PMMA-b-PAA),the molar ratio of the small organic conjugated ligand:rare-earth chloride:amphiphilic diblock polymer is 3:1:1,wherein the small organic conjugated ligand:rare-earth chloride:amphiphilic diblock polymer are subjected to complexation reaction for 5-10 hrs in an oil bath at 50-70° C., to obtain a solution of an organic rare-earth solid micelle that is a complex having a size of 10-20 nm.2. (canceled)3. The preparation method according to claim 1 , wherein the polymethyl methacrylate-b-polyacrylic acid (PMMA-b-PAA) useful as the amphiphilic diblock polymer is ...

Подробнее
09-01-2020 дата публикации

METHOD OF PREPARING METAL OXIDE-SILICA COMPOSITE AEROGEL AND METAL OXIDE-SILICA COMPOSITE AEROGEL PREPARED BY THE SAME

Номер: US20200010328A1
Автор: Kim Jong hun, Lee Je Kyun
Принадлежит:

Provided is a method of preparing a metal oxide-silica composite aerogel and a metal oxide-silica composite aerogel having an excellent weight reduction property prepared by the method. The method comprises adding an acid catalyst to a first water glass solution to prepare an acidic water glass solution (step ); adding a metal ion solution to the acidic water glass solution to prepare a precursor solution (step ); and adding a second water glass solution to the precursor solution and performing a gelation reaction (step ). 1. A method of preparing a metal oxide-silica composite aerogel , the method comprising:1) adding an acid catalyst to a first water glass solution to prepare an acidic water glass solution;2) adding a metal ion solution to the acidic water glass solution to prepare a precursor solution; and3) adding a second water glass solution to the precursor solution and performing a gelation reaction.2. The method according to claim 1 , wherein the pH of the acidic water glass solution is 0.1 to 2.9.3. The method according to claim 1 , wherein a reaction temperature while performing the gelation reaction is 10 to 100° C.4. The method according to claim 1 , wherein a reaction temperature while performing a gelation reaction is 10 to 80° C.5. The method according to claim 1 , wherein a concentration of the precursor solution is 0.1 to 3.9% by weight based on 1 L of a solvent.6. The method according to claim 1 , wherein a concentration of the precursor solution is 0.1 to 3.0% by weight based on 1 L of a solvent.7. The method according to claim 1 , wherein a concentration of the first water glass solution is 0.01 M to 2.0 M.8. The method according to claim 1 , wherein a concentration of the metal ion solution is 0.01 M to 2.0 M.9. The method according to claim 1 , wherein a concentration of the second water glass solution is 0.5 M to 6.0 M.10. The method according to claim 1 , wherein a concentration of the second water glass solution is higher than a ...

Подробнее
11-01-2018 дата публикации

Ferrite particle having outer shell structure

Номер: US20180011414A1
Автор: Koji Aga, Takao Sugiura
Принадлежит: Powdertech Co Ltd

An object of the present invention is to provide a ferrite particle having a low apparent density, filling a specified volume with a low weight with various properties maintained in a controllable state, a ferrite carrier core material composed of the ferrite particle, and a ferrite carrier using the ferrite core material and an electrophotographic developer. To achieve the object, the ferrite particle having the outer shell structure containing the Ti oxide for the ferrite carrier core material, and the ferrite carrier using the ferrite particle as the ferrite carrier core material and the electrophotographic developer are employed.

Подробнее
03-02-2022 дата публикации

A METHOD OF PRODUCING CAPSULES AND RELATED CAPSULES

Номер: US20220032254A1
Принадлежит:

There is provided a method of producing silica capsules, the method comprising: adding a silica precursor to emulsified droplets in the presence of salt and alcohol to enhance silica growth around the emulsified droplets by an ion association effect, thereby forming silica capsules. Also provided are silica capsules producible by such a method. 1. A method of producing silica capsules , the method comprising:adding a silica precursor to emulsified droplets in the presence of salt and alcohol to enhance silica growth around the emulsified droplets by an ion association effect, thereby forming silica capsules.2. The method of claim 1 , wherein the salt is present at a concentration of from 10 mM to 20 mM.3. The method of claim 1 , wherein the alcohol is present at a concentration of at least about 20% v/v.4. The method of claim 1 , wherein the adding step is carried out in an acidic pH environment.5. The method of claim 4 , wherein the acidic pH is from pH 2 to pH 5.6. The method of claim 1 , wherein the salt comprises an inorganic salt.7. The method of claim 6 , wherein the inorganic salt comprises a metal salt.8. The method of claim 1 , wherein the alcohol is selected from the group consisting of: methanol claim 1 , ethanol claim 1 , propanol claim 1 , isopropanol and combinations thereof.9. The method of claim 1 , wherein the silica precursor comprises an alkoxy silane.10. The method of claim 1 , wherein the method is carried out at a temperature of no more than about 60° C.11. The method of claim 1 , wherein the emulsified droplets are substantially non-polar.12. The method of claim 1 , further comprising dispersing a substantially non-polar substance in a polar solvent to obtain the emulsified droplets.13. The method of claim 1 , further comprising evaporating the emulsified droplets encapsulated by the silica capsules to obtain hollow silica capsules.14. The method of claim 1 , wherein the method is carried out using water as the primary medium.15. The method of ...

Подробнее
19-01-2017 дата публикации

PROCESS FOR PRODUCING AEROGELS BY DIELECTRIC HEATING

Номер: US20170014792A1
Принадлежит: ENERSENS

The present invention relates to a process for producing aerogels, comprising the following successive steps: a) formation or casting of a sol in a reactor, optionally in the presence of a reinforcing material and/or an additive, b) complete gelling of the sol into a lyogel; c) optionally hydrophobization of the lyogel resulting in a hydrophobized lyogel; d) drying of the optionally hydrophobized lyogel so as to obtain an aerogel; said process being characterized in that the complete gelling step b) comprises dielectric heating by microwave or high-frequency electromagnetic irradiation, inducing an increase in temperature so as to reach a set temperature for complete gelling Tin a range of from 100° C. to 200° C., preferably from 100° C. to 150° C., the temperature Tbeing maintained in this range for a period of time U sufficient to attain complete gelling of the lyogel, and more particularly the end of syneresis of the lyogel. 115-. (canceled)16. Aerogel manufacturing process comprising the following successive steps:a) forming or pouring a sol into a reactor, optionally in the presence of a reinforcing material and/or an additive,b) complete jelling of the sol into a lyogel;c) optionally hydrophobing the lyogel leading to a hydrophobic lyogel;d) drying the optionally hydrophobic lyogel to obtain an aerogel;{'sub': b', 'b', '1, 'said process being characterized in that complete jellification step b) comprises dielectric heating by microwave or high-frequency electromagnetic irradiation inducing an increase in temperature to reach a complete jellification setpoint temperature Tin a range from 100° C. to 200° C., temperature Tbeing maintained in this range for a time tsufficient to reach the end of complete jellification of the lyogel, and more particularly completion of syneresis of the lyogel.'}17. The process of claim 16 , wherein time tis at least 6 minutes and less than or equal to 1 hour.18. The process of claim 16 , wherein temperature Tis comprised between ...

Подробнее
19-01-2017 дата публикации

Single Use, Low Dead Volume Apparatus For Liposome Sizing or Extrusion

Номер: US20170014793A1
Принадлежит:

A single-use, extrusion apparatus and method of using the apparatus. The apparatus includes a first housing member having a first port dimensioned to receive a first needle-tipped syringe, and a first needle path dimensioned to receive a first needle, wherein the first needle path extends from the first port through the first housing member; a second housing member having a second port dimensioned to receive a second needle-tipped syringe, and a second needle path, dimensioned to receive a second needle, wherein the second needle path extends from the second port through the second housing member and is collinear with the first needle path extending through the first housing member; and a membrane filter disposed between the first and second housing members, wherein a total dead-volume of the apparatus, not including the first and second needle paths is less than or equal to about 50 microliters. 1. A single-use , low dead-volume extrusion apparatus comprising:a) a first plastic housing member comprising a first port dimensioned to receive a first needle-tipped syringe, and further comprising a first needle path dimensioned to receive a first needle, wherein the first needle path extends from the first port through the first housing member;b) a second plastic housing member comprising a second port dimensioned to receive a second needle-tipped syringe, and further comprising a second needle path, dimensioned to receive a second needle, wherein the second needle path extends from the second port through the second housing member and is collinear with the first needle path extending through the first housing member; andc) a membrane filter disposed between the first and second plastic housing members for interrupting fluid flow from the first needle path to the second needle path,wherein the first port is in fluid communication with the second port via the first needle path and the second needle path, and wherein the first housing member and the second housing member ...

Подробнее
15-01-2015 дата публикации

LIPOSOMES ACTIVE IN-VIVO ON NEURODEGENERATIVE DISEASES

Номер: US20150017235A1
Принадлежит:

New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease. 1. Liposomes comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E or derivatives thereof.2. Liposomes according to claim 1 , wherein the component (i) is present in an approximate 1-20% molar percentage claim 1 , more preferably in an approximate 1-10% claim 1 , most preferably in an approximate 5% molar amount.3. Liposomes according to claim 1 , wherein the component (ii) is present in an approximate 1-5% molar amount.4. Liposomes according to claim 1 , wherein the component (ii) is an apolipoprotein E fragment comprised within the portion from amino acid residue 100 to amino acid residue 200 of Apolipoprotein E amino acid sequence.5. Liposomes according to claim 1 , wherein the component (ii) corresponds to the sequence from amino acid residue 141 to amino acid residue 150 of apolipoprotein E claim 1 , or a dimer thereof.6. Liposomes according to claim 1 , wherein said apolipoprotein E or derivative thereof has a C-terminal end and includes claim 1 , at said C-terminal end claim 1 , a cystein-ending peptide of up to five aminoacids.7. Liposomes according to claim 6 , wherein the cystein-ending peptide is the tripeptide CWG-.8. Liposomes according to claim 1 , wherein the component (ii) is chemically linked via a linker molecule.9. Liposomes according to claim 1 , including further standard liposome lipids.10. Liposomes according to claim 9 , wherein the standard liposomes lipids are selected from the group consisting of one or more among sphingomyelin claim 9 , phosphatidylcholine claim 9 , phosphatidylethanolamine claim 9 , PEGylated phosphatidylethanolamine claim 9 , ...

Подробнее
18-01-2018 дата публикации

A Composition Containing Protective Agent for Singlet Oxygen and A Preparation Method therefor

Номер: US20180015164A1
Принадлежит: NANJING UNIVERSITY

The Invention relates to a method to utilize the characteristic of a protective agent to incubate singlet oxygen and prolong its lifetime so as to provide abundant singlet oxygen with persistence and thus improve the effect of photodynamic therapy. The composition is composed of a functional substance that can prolong the lifetime of singlet oxygen, an emulsifier and a photosensitizer; the functional substance is emulsified into an emulsion through the emulsifier and delivered into a tumor tissue with the photosensitizer; then the photodynamic therapy can be conducted with the abundant singlet oxygen incubated by the functional substance that can prolong the lifetime of singlet oxygen and thus the effect of photodynamic therapy is improved. 1. A preparation method for a composition containing protective agent for singlet oxygen; the composition is composed of an emulsifier , a photosensitizer and a protective agent , wherein , the preparation method comprises the following steps:(a) Dissolving the photosensitizer and the emulsifier with a solvent to obtain a mixed solution;(b) Adding the protective agent for singlet oxygen into the mixed solution and emulsifying the protective agent in ice bath to prepare the composition.2. The preparation method according to claim 1 , wherein claim 1 , the solvent in Step (a) is one or more of dichloromethane claim 1 , trichloromethane claim 1 , ethyl alcohol claim 1 , methyl alcohol and propyl alcohol.3. The preparation method according to claim 1 , wherein claim 1 , the emulsifying method in Step (b) is an extrution method claim 1 , an ultrasonic method or a high-speed dispersion method.4. The preparation method according to claim 1 , wherein claim 1 , the photosensitizer in Step (a) is hydrophilic claim 1 , lipophilic or amphipathic claim 1 , which is selected from one or more of porphyrin and its derivatives as ICG claim 1 , Ce6 and 5-ALA; chlorophyll and its derivatives as phaeophytin claim 1 , chlorin and purpurin 18; ...

Подробнее
17-01-2019 дата публикации

Engineered Exosomes for the Delivery of Bioactive Cargo Using Transmembrane VSV-G

Номер: US20190015333A1
Принадлежит:

Vesicular stomatitis virus glycoprotein (VSVG) can both load protein cargo onto exosomes and increase their delivery ability via a pseudotyping mechanism. By fusing a set of fluorescent and luminescent reporters with VSVG, we show the successful targeting and incorporation of VSVG fusions into exosomes by gene transfection and fluorescence tracking. VSVG pseudotyping of exosomes does not affect the size or distributions of the exosomes, and both the full-length VSVG and the VSVG without the ectodomain integrate into the exosomal membrane, suggesting that the ectodomain is not required for protein loading. Finally, exosomes pseudotyped with full-length VSVG are internalized by multiple-recipient cell types to a greater degree compared to exosomes loaded with VSVG without the ectodomain, confirming a role of the ectodomain in cell tropism. This invention provides a new genetically encoded pseudotyping platform to load and enhance the intracellular delivery of therapeutic proteins via exosome-based vehicles to target cells. 1. An engineered exosome for the delivery of bioactive cargo , comprising:an exosome defining an inner-vesicle space and an outer-vesicle space, wherein the exosome incorporates a vesicular stomatitis virus glycoprotein (VSVG) transmembrane anchoring scaffold onto the membrane of the exosome,wherein the VSVG transmembrane anchoring scaffold has a C-terminal attachment site in the inner-vesicle space,wherein the VSVG transmembrane anchoring scaffold has a N-terminal attachment on the outer-vesicle space,wherein a first peptide is attached to the C-terminal attachment site of the VSVG transmembrane anchoring scaffold so that the first peptide is located in the inner-vesicle space,wherein a second peptide is attached to the N-terminal attachment site of the VSVG transmembrane anchoring scaffold so that the second peptide is located in in the outer-vesicle space2. The engineered exosome as set forth in claim 1 , wherein the second peptide is attached to ...

Подробнее
21-01-2016 дата публикации

COMBINED MICROSPHERE MANUFACTURING APPARATUS

Номер: US20160016138A1
Принадлежит:

A main micro channel layer with a liquid leading-in plate assembled above and a microsphere leading-out plate assembled below. The liquid leading-in plate has a first and two second fluid outlets, and the microsphere leading-out plate has a microsphere outlet. The main micro channel layer has a main, two secondary, and a hybrid micro channels, the main micro channel being communicated with the first fluid outlet, the two secondary micro channels being located at two sides of the main micro channel and intersecting with the main micro channel at an intersection in a cross or a Y junction, the two secondary micro channels communicated with the two second fluid outlets, and the hybrid micro channel connected to the intersection and having an output end. A channel bottom surface of the main micro channel or the two secondary micro channels has an ascending slope to form an inclined inlet.

Подробнее
21-01-2016 дата публикации

Antibubble generator and preparation method

Номер: US20160016139A1
Принадлежит: Institute of Acoustics CAS

The present invention relates to an antibubble generator and a preparation method. The antibubble preparation method includes: generating a jet flow or droplets in a discrete phase from a first fluid through a gas phase; and under the action of an external force, the jet flow or droplets passing through a liquid membrane and moving towards a second fluid in a continuous phase, to form antibubbles. The present invention can generate a large number of antibubbles in a simple and convenient way, and can meet the needs of large-scale industrial applications.

Подробнее
17-01-2019 дата публикации

HYPERCOMPRESSED PHARMACEUTICAL FORMULATIONS

Номер: US20190015336A1
Принадлежит:

A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50,000 to 350,000 psi. 1. A pharmaceutical dosage form which comprises a lactide , glycolide or lactide-glycolide polymer , a block polymer of polyglycolide and trimethylene carbonate or a block polymer of poly-caprolactone and trimethylene carbonate or polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50 ,000 to 350 ,000 psi.2. A pharmaceutical dosage form as defined in where the therapeutic agent is selected from the group consisting of recombinant proteins claim 1 , antibodies for therapy claim 1 , immunotoxins claim 1 , cytokines and ECM proteins.3. A pharmaceutical dosage form as defined in where the polymer is selected from the group consisting of poly(dl-lactide) claim 1 , polyglycolide claim 1 , poly(glycolide-co-lactide) claim 1 , poly(glycolide-co-dl-lactide) or a mixture of any of the foregoing.4. A pharmaceutical dosage form as defined in where the lactide claim 1 , glycolide or lactide-glycolide claim 1 , or poly-caprolactone polymer is acid capped.5. A pharmaceutical dosage form as defined in where the lactide claim 1 , glycolide or lactide-glycolide claim 1 , or poly-caprolactone polymer is ester capped.6. A pharmaceutical dosage form as defined in where the microparticles have been compressed by the application of 50K psi to 170K psi.7. A pharmaceutical dosage form as defined in where the microparticles have been compressed by the application of 100 Kpsi to 300 Kpsi.8. A pharmaceutical dosage form as defined in where the microparticles have been compressed by the application of 60 Kpsi to 170 Kpsi.9. A pharmaceutical dosage form ...

Подробнее
17-01-2019 дата публикации

RADIATION STERILIZATION OF HYPERCOMPRESSED POLYMER DOSAGE FORMS

Номер: US20190015347A1
Принадлежит:

A sterile pharmaceutical dosage form which comprises an ester capped lactide polymer, glycolide polymer or a lactide-glycolide copolymer hypercompressed with an active pharmaceutical ingredient wherein said sterile pharmaceutical dosage form has been sterilized with an electron beam and a method of preparing said sterile pharmaceutical dosage form. 1. A sterile pharmaceutical dosage form which comprises an ester capped lactide polymer , glycolide polymer or a lactide-glycolide copolymer hypercompressed with an active pharmaceutical ingredient wherein said sterile pharmaceutical dosage form has been sterilized with an electron beam.2. A sterile pharmaceutical dosage form as defined in where the active pharmaceutical pharmaceutical ingredient is selected from the group consisting of steroids claim 1 , non-steroidal anti-inflammatory drugs claim 1 , antihistamines claim 1 , antibiotics claim 1 , mydriatics claim 1 , beta-adrenergic antagonists anesthetics claim 1 ,alpha-2-beta adrenergic agonists claim 1 , mast cell stabilizers claim 1 , prostaglandin analogues claim 1 , sympathomimetics claim 1 , parasympathomimetics claim 1 , antiproliferative agents claim 1 , agents to reduce ocular angiogenesis and neovascularization claim 1 , vasoconstrictors claim 1 , anti-neoplastic agents claim 1 , a polynucleotide claim 1 , or a recombinant protein analog an angiogenic inhibitors and combinations thereof.3. A sterile pharmaceutical dosage form as defined in where the polymer is selected from the group consisting of poly(dl-lactide) claim 1 , polyglycolide claim 1 , poly(glycolide-co-lactide) claim 1 , poly(glycolide-co-dl-lactide) claim 1 , a block polymer of polyglycolide claim 1 , trimethylene carbonate and polyethylene oxide claim 1 , or a mixture of any of the foregoing.4. A sterile pharmaceutical dosage form as defined in where the microcapsule has been compressed by the application of 50 Kpsi to 350 Kpsi.5. A sterile pharmaceutical dosage form as defined in where the ...

Подробнее
18-01-2018 дата публикации

CONVERSION OF ADDITIVELY MANUFACTURED ORGANIC POLYMER PARTS TO SUBSTANTIALLY PURE CARBON

Номер: US20180016145A1
Принадлежит:

In one embodiment, a method includes creating a three-dimensional, carbon-containing structure using an additive manufacturing technique and converting the three-dimensional, carbon-containing structure to a substantially pure carbon structure. Moreover, the substantially pure carbon structure has an average feature diameter of less than about 100 nm. In another embodiment, a product includes a substantially pure carbon structure having an average feature diameter of less than about 100 nm. In yet another embodiment, a product includes an aerogel having inner channels corresponding to outer walls of a three-dimensional printed template around which the aerogel was formed. In addition, the inner channels have an average feature diameter of less than about 100 nm. 1. A method , comprising:creating a three-dimensional, carbon-containing structure using an additive manufacturing technique,converting the three-dimensional, carbon-containing structure to a substantially pure carbon structure,wherein the substantially pure carbon structure has an average feature diameter of less than about 100 nm.2. The method of claim 1 , wherein the substantially pure carbon structure has at least one of an edge and a diameter of at least 1 mm in length.3. The method of claim 1 , wherein the substantially pure carbon structure has at least one of an edge and a diameter of at least 1 cm in length.4. The method of claim 1 , wherein converting the three-dimensional claim 1 , carbon-containing structure to the substantially pure carbon structure includes heating the three-dimensional claim 1 , carbon-containing structure in a vacuum.5. The method of claim 4 , wherein the heating is performed in a sequence of steps claim 4 , each step including an increasing heating rate and a holding period at a predefined temperature.6. The method of claim 1 , wherein converting the three-dimensional claim 1 , carbon-containing structure to the substantially pure carbon structure includes heating the three- ...

Подробнее
18-01-2018 дата публикации

SELF-HEATING SEALANT OR ADHESIVE EMPLOYING MULTI-COMPARTMENT MICROCAPSULES

Номер: US20180016474A1
Принадлежит:

A self-heating sealant or adhesive may be formed using multi-compartment microcapsules dispersed within a sealant or adhesive. The multi-compartment microcapsules produce heat when subjected to a stimulus (e.g., a compressive force, a magnetic field, or combinations thereof). In some embodiments, the multi-compartment microcapsules have first and second compartments separated by an isolating structure adapted to rupture in response to the stimulus, wherein the first and second compartments contain reactants that come in contact and react to produce heat when the isolating structure ruptures. In some embodiments, the multi-compartment microcapsules are shell-in-shell microcapsules each having an inner shell contained within an outer shell, wherein the inner shell defines the isolating structure and the outer shell does not allow the heat-generating chemistry to escape the microcapsule upon rupture of the inner shell. 1. A self-heating sealant or adhesive , comprising:a sealant or adhesive;multi-compartment microcapsules distributed in the sealant or adhesive, wherein each multi-compartment microcapsule has a first compartment and a second compartment separated from each other by an isolating structure adapted to rupture in response to a stimulus, wherein the first and second compartments of each multi-compartment microcapsule contain reactants that come in contact and react to produce heat when the isolating structure ruptures.2. The self-heating sealant or adhesive as recited in claim 1 , wherein the stimulus is selected from a group consisting of a compressive force claim 1 , a magnetic field claim 1 , and combinations thereof.3. The self-heating sealant or adhesive as recited in claim 1 , wherein the sealant or adhesive is selected from a group consisting of an epoxy-based sealant claim 1 , an acrylic-based sealant claim 1 , a silicone-based sealant claim 1 , and combinations thereof.4. The self-heating sealant or adhesive as recited in claim 1 , wherein the ...

Подробнее
16-01-2020 дата публикации

Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods

Номер: US20200016170A1
Принадлежит:

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. 1. An intraocular implant comprising therapeutic polymeric microparticles , the microparticles made by the steps of:encapsulating a prostaglandin analog with a polymeric component to form a population of prostaglandin analog encapsulated microparticles by an oil-in-oil emulsion process, wherein the prostaglandin analog-encapsulated microparticles have an effective average particle size of less than about 3000 nanometers.2. The implant of claim 1 , wherein the oil-in-oil emulsion process comprises forming an oil-in-oil emulsion containing the prostaglandin analog and the polymeric component; drying the emulsion to form a dried emulsion product; contacting the dried emulsion product with a solvent to form a solvent-containing composition; and removing the solvent from the solvent-containing composition to form the population of microparticles comprising the prostaglandin analog and the polymeric component.38.-. (canceled)9. The implant of claim 1 , wherein the prostaglandin analog of the microparticles so produced is encapsulated by the polymeric component to preserve therapeutic activity of the prostaglandin analog after a terminal sterilization procedure.10. The implant of claim 1 , wherein the polymeric component comprises a biodegradable polymer or biodegradable copolymer.11. ...

Подробнее
16-01-2020 дата публикации

LAYERED PARTICLES AND PROCESSES THEREOF

Номер: US20200016562A1
Автор: PANAGIOTOU Thomai
Принадлежит:

Process for the preparation of layered particles are provided. Layered particles prepared by such processes are also provided 1116-. (canceled)117. A process for the preparation of layered particles comprising: (i) introducing one or more core particles into a first liquid carrier;', '(ii) mixing the one or more core particles in the first liquid carrier to form a first mixture;', '(iii) optionally, homogenizing the first mixture; and', '(iv) introducing one or more reactants into the first mixture;, '(a) forming a first liquid stream comprising (i) introducing one or more reactants into a second liquid carrier;', '(ii) mixing the one or more reactants in the second liquid carrier to form a second mixture; and', '(iii) optionally, homogenizing the second mixture;, '(b) forming a second liquid stream comprising(c) continuously pumping the first liquid stream into a first port of a multi-port mixing device, wherein the first liquid stream is pumped into the mixing device at a fraction of the flow rate of the mixing device;(d) continuously pumping the second liquid stream into a second port of the multi-port mixing device; and{'sup': 3', '10, '(e) mixing the first liquid stream and the second liquid stream inside the mixing device for an effective period of time to form a layer on the one or more core particles, wherein the mixing device is capable of producing an average energy rate per kilogram of the mixture of liquid streams of from about 10to about 10W/kg.'}118. The process of claim 117 , wherein step (a)(iv) further comprises introducing one or more surfactants into the first mixture.119. The process of claim 117 , wherein step (b)(i) further comprises introducing one or more surfactants into the second liquid carrier.120. The process of claim 117 , wherein step (a) further comprises washing the one or more core particles.121. The process of claim 117 , wherein the effective period of time is from about 1 microsecond to about 1 hour.122. The process of claim 120 ...

Подробнее
16-01-2020 дата публикации

PREPARATION METHOD OF CARBON-COATED CERIA HOLLOW SPHERE

Номер: US20200016565A1
Принадлежит:

The present disclosure discloses a method of preparing a carbon-coated ceria hollow sphere, which includes the following steps of: S dispersing silica in a solvent to obtain a silica dispersion; S performing a hydrothermal reaction between the silica dispersion and a cerium salt to obtain a ceria-coated silica microsphere; S coating the ceria-coated silica microsphere with a carbon source to obtain a primary product, wherein the carbon source is dopamine; S sintering the primary product under a protective gas atmosphere to obtain a carbon-coated ceria microsphere; and S etching the carbon-coated ceria microsphere by using an etchant to obtain a carbon-coated ceria hollow sphere. 1. A method of preparing a carbon-coated ceria hollow sphere , comprising the following steps of:dispersing silica in a solvent to obtain a silica dispersion;performing a hydrothermal reaction between the silica dispersion and a cerium salt to obtain a ceria-coated silica microsphere;coating the ceria-coated silica microsphere with a carbon source to obtain a primary product, wherein the carbon source is dopamine;sintering the primary product under a protective gas atmosphere to obtain a carbon-coated ceria microsphere; andetching the carbon-coated ceria microsphere by using an etchant to obtain a carbon-coated ceria hollow sphere.2. The preparation method of claim 1 , wherein the step of coating the ceria-coated silica microsphere with the carbon source to obtain the primary product is specifically:adding the ceria-coated silica microsphere into a trihydroxymethyl aminomethane buffer solution with a pH of 7.4 to 9.0; andadding dopamine under a temperature of 15° C. to 35° C. and mixing for 1 h to 24 h to obtain the primary product.3. The preparation method of claim 2 , wherein an amount ratio of the ceria-coated silica microsphere to the trihydroxymethyl aminomethane buffer solution ranges from 0.5 mg/mL to 20 mg/mL.4. The preparation method of claim 1 , wherein a mass ratio of the ceria- ...

Подробнее
21-01-2021 дата публикации

METHOD OF PREPARING METAL OXIDE-SILICA COMPOSITE AEROGEL AND METAL OXIDE-SILICA COMPOSITE AEROGEL PREPARED BY THE SAME

Номер: US20210016239A1
Автор: Kim Jong hun, Lee Je Kyun
Принадлежит:

Provided are a method of preparing a metal oxide-silica composite aerogel, and a metal oxide-silica composite aerogel having an excellent weight reduction property prepared by the method. The method includes a step of adding an acid catalyst to a first water glass solution to prepare an acidic water glass solution (step 1); a step of adding a metal ion solution to the acidic water glass solution to prepare a precursor solution (step 2); and a step of adding a second water glass solution to the precursor solution and performing a gelation reaction (step 3) to yield a metal oxide-silica composite wet gel, wherein, in steps 2 and 3, bubbling of an inert gas is performed during the adding of the metal ion solution or the second water glass solution, respectively. 1. A method of preparing a metal oxide-silica composite aerogel , the method comprising:1) adding an acid catalyst to a first water glass solution to prepare an acidic water glass solution;2) adding a metal ion solution to the acidic water glass solution to prepare a precursor solution; and3) adding a second water glass solution to the precursor solution and performing a gelation reaction to yield a metal oxide-silica composite wet gel,wherein, in steps 2) and 3), bubbling of an inert gas is performed with an inert gas during the adding of the metal ion solution or the second water glass solution, respectively.2. The method according to claim 1 , wherein the inert gas comprises one or more of helium (He) claim 1 , neon (Ne) claim 1 , argon (Ar) claim 1 , krypton (Kr) claim 1 , xenon (Xe) claim 1 , radon (Rn) claim 1 , nitrogen (N) claim 1 , and carbon dioxide (CO) gases.3. The method according to claim 1 , wherein the pH of the acidic water glass solution is 0.1 to 2.9.4. The method according to claim 1 , wherein the concentration of the first water glass solution is 0.01 M to 2.0 M.5. The method according to claim 1 , wherein the concentration of the metal ion solution is 0.01 M to 2.0 M.6. The method ...

Подробнее
17-01-2019 дата публикации

LOW DENSITY CLOSED CELL COMPOSITE AEROGEL FOAM AND ARTICLES INCLUDING SAME

Номер: US20190016957A1
Принадлежит:

A composite foam is provided having silica aerogel particles dispersed in a closed cell polymeric foam. The silica aerogel particles are included in a volume fraction between 2 and 60%, and the composite foam has a thermal conductivity of 40 kW/mK or less and a density of 60 kg/mor less. In another embodiment, a composite foam is provided having a perforated closed cell polymeric foam and 2-60% hydrophobic silica aerogel particles by volume with a particle size distribution of 1 to 50 where the composite foam has a thermal conductivity of 30 kW/mK or less, a density of 20-45 kg/m, and an air permeability of 20-40 cubic feet per minute. 1. A composite foam comprising:silica aerogel particles dispersed in a closed cell polymeric foam,{'sup': '3', 'wherein the composite foam includes the silica aerogel particles in a volume fraction between 2 and 60%, and has a thermal conductivity of 40 kW/mK or less and a density of 60 kg/mor less.'}2. The composite foam of claim 1 , wherein the density is 50 kg/mor less.3. The composite foam of claim 1 , wherein the density is 20-45 kg/m.4. The composite foam of claim 1 , wherein the density is 30-40 kg/m.5. The composite foam of claim 1 , wherein the thermal conductivity is 30 kW/mK or less.6. The composite foam of claim 1 , wherein the silica aerogel particles are hydrophobic.7. The composite foam of claim 6 , wherein a water absorption of the composite foam is 0.1% by volume or less.8. The composite foam of claim 1 , wherein the composite foam has an average thickness between 1.5 to 6 mm.9. The composite foam of claim 1 , wherein the composite foam includes perforations having a diameter of 1 mm or less.10. The composite foam of claim 1 , wherein the composite foam is perforated with an air permeability of 5-60 cubic feet per minute.11. The composite foam of claim 1 , wherein the silica aerogel particles are included in a volume fraction from 3-40%.12. The composite foam of claim 1 , wherein the silica aerogel particles have a ...

Подробнее
18-01-2018 дата публикации

CELLULOSE CAPSULES

Номер: US20180019036A1
Автор: Cohen Yachin, Rein Dmitry
Принадлежит:

A method for making an oil-in-water dispersion or water-in-oil dispersion is disclosed. The method comprises the step of mixing a hydrophilic medium, a hydrophobic composition and non-derivatized cellulose solution in an ionic liquid. 1. A method for making an oil-in-water dispersion or water-in-oil dispersion , comprising the step of mixing a hydrophilic medium , a hydrophobic composition and non-derivatized cellulose solution in an ionic liquid.2. The method of claim 1 , wherein said oil-in-water dispersion or said water-in-oil dispersion is in the form of one or more particles.3. The method of claim 1 , wherein said mixing is mixing in the absence of a surfactant.4. The method of claim 1 , wherein said non-derivatized cellulose solution is a hydrogel.5. The method of claim 4 , wherein said hydrogel is formed by coagulating a cellulose/IL solution with water.6. The method of claim 1 , wherein said non-derivatized cellulose is an emulsifying agent.7. The method of claim 1 , further comprising drying a solid-state dispersion of the oil-in-water dispersion or the water-in-oil dispersion thereby conserving said solid-state dispersion.8. The method of claim 1 , further comprising a subsequent fermenting step claim 1 , thereby obtaining biofuel. A composition having an interior hydrophobic space encapsulated by at least one non-derivatized cellulose molecular layer surrounded by a hydrophilic medium and methods for hydrolyzing cellulose and making an oil-in-water dispersion or water-in-oil dispersion, are provided.Encapsulation is a process in which tiny particles or droplets are surrounded by a coating to impart many useful properties to small capsules. In a relatively simplistic form, a microcapsule is a small sphere with a uniform wall around it. The material inside the microcapsule is referred to as the core, internal phase, or fill, whereas the wall is sometimes called a shell, coating, or membrane. Most microcapsules have diameters between a few microns to a few ...

Подробнее
25-01-2018 дата публикации

Method for producing molecular assemblies, and device for producing molecular assemblies

Номер: US20180021748A1
Принадлежит: Shimadzu Corp

The present invention relates to a method and an apparatus both for producing molecular assemblies of an amphiphilic block polymer. The method of the present invention includes: applying a polymer solution ( 45 ) containing an amphiphilic block polymer and a solvent in a layered shape on a planar base member ( 11 ) in a film forming part ( 40 ); forming a polymer film on the base member ( 13 ) by removing the solvent from the coated layer of the solution in a drying part ( 30 ); and producing molecular assemblies by bringing the polymer film into contact with a water-based liquid ( 55 ) in a molecular assembly forming part ( 50 ). The amphiphilic block polymer has a hydrophilic block chain and a hydrophobic block chain. The hydrophilic block chain preferably has 20 or more sarcosine units, and the hydrophobic block chain preferably has 10 or more lactic acid units.

Подробнее
25-01-2018 дата публикации

LUTEIN MICROCAPSULE FORMULATION AND PREPARATION METHOD THEREOF

Номер: US20180021749A1
Принадлежит:

A lutein microcapsule formulation and preparation method thereof, the formulation comprising the following ingredients: lutein crystals, a water-soluble emulsifier, an oil-soluble antioxidant, a wall material, a filler, a water-soluble antioxidant, and purified water. The preparation method comprises: dissolving the lutein crystals and the oil-soluble antioxidant in the water-soluble emulsifier to obtain an oil phase; adding the wall material, the water-soluble antioxidant, and the filler to the purified water to obtain a water phase; adding the oil phase to the water phase, grinding to obtain a particle size of the liquid emulsion of less than 100 nm, and granulating. 1. A lutein microcapsule formulation comprising the following ingredients: lutein crystals , oil-soluble antioxidant , water-soluble emulsifier , wall material , filler , water-soluble antioxidant and purified water.2. The formulation according to claim 1 , characterized in that claim 1 , the formulation comprises the following ingredients in parts by weight: 1 part of lutein crystals claim 1 , 0.1-0.5 parts of oil-soluble antioxidant claim 1 , 0.3-1.0 parts of water-soluble emulsifier claim 1 , 3.0- 4.0 parts of wall material claim 1 , 4.0-5.0 parts of filler claim 1 , 0.2-1.0 parts of water-soluble antioxidant claim 1 , and 8.0-12.5 parts of purified water.3. The formulation according to claim 2 , characterized in that claim 2 , the formulation comprises the following ingredients in parts by weight: 1 part of lutein crystals claim 2 , 0.1-0.3 parts of oil-soluble antioxidant claim 2 , 0.5-1.0 parts of water-soluble emulsifier claim 2 , 3.5-3.75 parts of wall material claim 2 , 4.5-4.75 parts of filler claim 2 , 0.5-0.8 parts of water-soluble antioxidant claim 2 , and 10-11.5 parts of purified water.4. The formulation according to claim 1 , characterized in that claim 1 , the oil-soluble antioxidant is natural vitamin E or rosemary extract.5. The formulation according to claim 1 , characterized in ...

Подробнее
26-01-2017 дата публикации

CONSUMER PRODUCTS HAVING AN ASEPSIS CONNOTATION

Номер: US20170022458A1
Принадлежит:

The present application relates to perfume compositions, delivery systems comprising such perfumes products comprising such perfumes and/or delivery systems, and processes for making and using same. Such perfume compositions, delivery systems comprising such perfumes and products containing such perfumes and/or delivery systems can deliver a character that can signal/connotes that a situs treated with such materials has superior cleanliness and is essentially asepsis. 1. A consumer product comprising:a) a perfume selected from the group consisting of Table 1 perfumes 1, 3, 4, and 5; andb) a cleaning and/or treatment ingredient.2. A perfume delivery system selected from the group consisting of a Polymer Assisted Delivery (PAD) system , Molecule-Assisted Delivery (MAD) system , Cyclodextrin (CD) system , Starch Encapsulated Accord (SEA) system , Zeolite & Inorganic Carrier (ZIC) system , said perfume delivery system comprising a perfume selected from the group consisting of Table 1 perfumes 1 , 3 , 4 , and 5.3. A Polymer Assisted Delivery (PAD) system according to claim 2 , wherein said Polymer Assisted Delivery (PAD) system comprises a Polymer Assisted Delivery (PAD) Reservoir system claim 2 , preferably said Polymer Assisted Delivery (PAD) Reservoir system comprises a perfume delivery particle that comprises a shell material and a core material claim 2 , said shell material encapsulating said core material claim 2 , said core material comprising a perfume a perfume selected from the group consisting of Table 1 perfumes 1 claim 2 , 3 claim 2 , 4 claim 2 , and 5; said shell comprising a material selected from the group consisting of polyethylenes; polyamides; polystyrenes; polyisoprenes; polycarbonates; polyesters; polyacrylates; aminoplasts; and mixtures thereof.4. The Polymer Assisted Delivery (PAD) Reservoir system of wherein said shell comprises melamine formaldehyde and/or cross linked melamine formaldehyde.5. The Polymer Assisted Delivery (PAD) Reservoir system ...

Подробнее
24-01-2019 дата публикации

Systems, Methods, and Devices for Production of Gas-Filled Microbubbles

Номер: US20190022617A1

Gas-filled microbubbles can be synthesized using a continuous flow chamber and a sonicator. The resulting microbubble solution can be size-sorted for a particular application, such as injection into a patient for gas delivery thereto. The microbubble solution may be concentrated to have greater than 50% volume gas while maintaining microbubble sizes below 10 μm. Control of the microbubble generation process can yield highly stable microbubbles. The microbubbles may retain over half of their original gas payload for over three weeks while exhibiting minimal change in microbubble size. The systems, methods, and devices described herein thus allow for continuous or batch-wise continuous production of gas-filled microbubbles that readily release their gas payload when introduced into an under-saturated or de-saturated solution. 1. A method for generating microbubbles , comprising:flowing a lipid solution at a first flow rate into a reaction volume of a continuous flow chamber, the reaction volume having an end of a sonicator member located therein;flowing gas at a first pressure into the reaction volume at a same time as the flowing a lipid solution;ultrasonically agitating an interface between the lipid solution and the gas in the reaction volume using said sonicator member so as to generate a solution of gas-filled microbubbles; andduring the ultrasonically agitating, adjusting at least the first pressure based on a location of the interface in the reaction volume with respect to the end of the sonicator member,ensuring the lipid solution ultrasonically agitated is saturated with a core gas to a level between 50% and 90%, inclusive, during the ultrasonically agitating.2. The method of claim 1 , further comprising claim 1 , after the ultrasonically agitating claim 1 , sorting the generated microbubbles responsively to size.3. The method of claim 1 , further comprising claim 1 , after the ultrasonically agitating claim 1 , sorting the generated microbubbles responsively ...

Подробнее
25-01-2018 дата публикации

MICROCAPSULES IMPARTING INTENSE VANILLA ODOR NOTE

Номер: US20180023033A1
Принадлежит: FIRMENICH SA

The present invention relates to microcapsules delivering long lasting and intense vanilla-based odor note. More particularly, the present invention concerns a microcapsule comprising between 10% and 30% by weight, relative to the total weight of the microcapsule, of a particular perfuming ingredient imparting a vanilla-based odor note, which can be used in perfuming compositions and perfuming consumer products. 2. A microcapsule according to claim 1 , characterized in that the compound of formula (I) is present in an amount comprised between 25% and 29% by weight claim 1 , relative to the total weight of the microcapsule.3. A microcapsule according to claim 1 , characterized in that the perfume oil consists essentially of a compound of formula (I) and a solvent.4. A microcapsule according to claim 1 , characterized in that the compound of formula (I) is 2-methoxy-4-methylphenyl methyl carbonate.5. A microcapsule according to claim 1 , characterized in that said microcapsule is formed by interfacial polymerization claim 1 , by a phase separation process induced by polymerization or by coacervation.6. Use of microcapsules as defined in claim in a perfuming composition or a perfuming consumer product 1 , for delivering a long lasting and intense vanilla-based note.7. A method to confer claim 1 , enhance or improve a vanilla-based odor note comprising applying microcapsules as defined in to a surface.8. A perfuming composition comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) as perfuming ingredient, a microcapsules as defined in ;'}b) at least one ingredient selected from the group consisting of a perfumery carrier and a perfumery co-ingredient; andc) optionally at least one perfumery adjuvant.9. A perfuming consumer product comprising as perfuming ingredient claim 1 , microcapsules according to .10. A perfuming consumer product according to claim 9 , characterized in that the product is a perfume claim 9 , a fabric care product claim 9 , a body-care ...

Подробнее
28-01-2021 дата публикации

A MICROCAPSULE AND PRODUCTION METHOD THEREOF

Номер: US20210023016A1
Принадлежит:

Disclosed is a microcapsule which is used in tissue regeneration, which may be specifically directed to the damaged tissues, and which forms an extracellular matrix-like structure at a certain point and thus allows cell proliferation, and to the production method of such microcapsule. 11. A microcapsule () which is used in tissue regeneration , which may be specifically directed to the damaged tissues , and which forms an extracellular matrix-like structure at a certain point , characterized in comprising:{'b': '2', 'at least one living cell (),'}{'b': 3', '2, 'at least one primary layer () enclosing the living cell (),'}{'b': 4', '3', '5', '5', '3', '3, 'at least one and at least one type of side group (), which is present between the primary layer () and the second layer (), and allows the second layer () to adhere to the primary layer () and thus create a multi-layer structure, and to which another layer to enclose the primary layer () is bound,'}{'b': 5', '51', '52', '53, 'at least one second layer () comprising at least one functionalized polymer (), at least one and at least one type of targeting factor (), and at least one enhancing tissue formation/accumulation (),'}{'b': 51', '3, 'a functionalized polymer () which is coated onto the primary layer () and which has the property of being targeted,'}{'b': 52', '51', '522', '521, 'a targeting factor (), which is present on the functionalized polymer (), allows targeting the damaged point, in which a scaffold is desired to be formed, and comprises a targeting agent () and a targeting bridge factor (),'}{'b': 53', '51', '5', '531', '532, 'a tissue formation/accumulation factor () which enhances the adhesion surface on the functionalized polymer (), forms coupling points on the second layer (), and comprises a tissue formation/accumulation bridge factor () and a tissue formation/accumulation point (),'}{'b': 531', '532', '512', '51', '532, 'at least one tissue formation/accumulation bridge factor (), at one end of ...

Подробнее
24-01-2019 дата публикации

Color Changing Materials Arranged in Slow Particle Coloration Materials

Номер: US20190025570A1
Принадлежит:

Articles comprises iron oxide colloidal nanocrystals arranged within chains, wherein the chains of nanocrystals are embedded within a material used to form the article or a transfer medium used to transfer a color to the article are described. The material or transfer medium includes elastic properties that allow the nanocrystals to display a temporary color determined by the strength of an external force applied to the article, and the material or transfer medium includes memory properties that cause the displayed temporary color to dissipate when the external force is removed, wherein the dissipation of the displayed temporary color is sufficiently slow as to be visually observable by an average observer's unaided eye. 135.-. (canceled)36. A material comprising iron oxide colloidal nanocrystals arranged within chains ,wherein each chain of nanocrystals is encapsulated with a polymer,wherein the polymer comprises properties that elongate the chains of nanocrystals when an external force is applied to the material, wherein the nanocrystals display a color when elongated, wherein the color dissipates when the external force is no longer applied to the material.37. The material of claim 36 , wherein the color change is within a visible light spectrum or an ultraviolet light spectrum.38. The material of claim 36 , wherein the polymer further comprises properties that allow the chains of nanocrystals to decrease permeability to infrared when the external force is applied to the material.39. The material of claim 36 , wherein the polymer is a hydrophilic elastomer and the external force is water.40. The material of claim 36 , wherein the external force is application of a magnetic field to the chains of nanocrystals.41. The material of claim 36 , wherein the external force is a physical force applied to the material claim 36 , which causes a localized deformation of the material.42. An article comprising iron oxide colloidal nanocrystals arranged within chains claim 36 , ...

Подробнее
28-01-2021 дата публикации

EMULSIONS, METHODS AND USES THEREOF

Номер: US20210024883A1

The present disclosure relates to emulsions, methods of preparation thereof, and uses of said emulsions to fabricate porous polymeric microspheres as microcarriers for cell culture. In particular, the present disclosure relates to an emulsion with enhanced stability, characterized in that the emulsion comprises a) a water phase, the water phase is an aqueous solution comprising a salt; and b) an oil phase, the oil phase comprising a polymer; wherein the oil phase is immiscible with the water phase, and wherein the density differential of the water phase and oil phase is less than about 0.02 g/cm3. In a preferred embodiment, the polymer is polycaprolactone (PCL). 1. An emulsion comprising:a) a water phase, the water phase is an aqueous solution comprising a salt; andb) an oil phase, the oil phase comprising a polymer;wherein the oil phase is immiscible with the water phase, and{'sup': '3', 'wherein the density differential of the water phase and oil phase is less than about 0.02 g/cm.'}2. The emulsion according to claim 1 , the emulsion is stable for at least 5 days.3. The emulsion according to or claim 1 , wherein the densities of the water phase and oil phase are independently from about 1 g/cmto about 1.7 g/cm.4. The emulsion according to any of to claim 1 , wherein the polymer has a concentration from about 10 mg/mL to about 250 mg/mL.5. The emulsion according to any of to claim 1 , wherein the polymer is selected from polycaprolactone (PCL) claim 1 , polylactic acid (PLA) claim 1 , polyglycolide (PGA) claim 1 , poly(lactic-co-glycolic acid) (PLGA) claim 1 , poly(glycolide-co-caprolactone) claim 1 , poly (glycolide-co-trimethylene carbonate) claim 1 , polystyrene (PS) claim 1 , polyethylene terephthalate (PET) or their copolymers thereof.6. The emulsion according to any of to claim 1 , wherein the salt is selected from potassium carbonate (KCO) claim 1 , potassium acetate (K(CHCO)) claim 1 , potassium bromide (KBr) claim 1 , potassium chloride (KCl) claim 1 , ...

Подробнее
02-02-2017 дата публикации

IMMUNOSUPPRESSANT FORMULATION

Номер: US20170027906A1
Принадлежит:

The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form. 1. A dosage form obtainable by a process comprising the stepsi) providing siponimod,ii) pre-blending the compound of step i) with moisture protective agent and optionally pharmaceutical excipient,iii) blending the mixture of step ii) with pharmaceutical excipient(s),iv) processing the mixture of step iii) to a dosage form,v) optionally, film-coating the dosage form.2. The dosage form according to containing 0.2 to 12% (w/w) siponimod claim 1 , 1 to 8% (w/w) of moisture-protective agent and 80 to 98.8% (w/w) of pharmaceutical excipient(s).3. The dosage form according to claim 1 , wherein siponimod is present in an amount of 0.2 to 10 mg claim 1 , based on the amount of siponimod in form of the free base.4. The dosage form according to claim 1 , wherein the in-vitro release of siponimod is not less than 80% after 30 minutes.5. The dosage form according to claim 1 , wherein the ratio of the siponimod particle size X90/X50 is 2 to 5.6. The dosage form according to claim 1 , wherein the moisture-protective agent has a n-octanol/water partition coefficient (log P) of 0.1 to 20 claim 1 , preferably 1 to 15.7. The dosage form according to claim 1 , wherein the moisture-protective agent is selected from hydrogenated vegetable oil claim 1 , castor oil claim 1 , palmitol stearate claim 1 , glyceryl palmitostearate and glyceryl behenate.8. The dosage form according to claim 1 , wherein the pharmaceutical excipients are selected from lubricants claim 1 , binders claim 1 , glidants claim 1 , disintegrants and fillers.9. The dosage form according to claim 1 , wherein the lubricant and the moisture-protective agent are the same compound claim 1 , wherein the combined amount of lubricant and moisture-protective agent is 1 to 16% (w/w).10. The dosage form according to claim 1 ...

Подробнее
04-02-2016 дата публикации

COMPOSITIONS INCLUDING APOLIPOPROTEIN AND METHODS USING FOCUSED ACOUSTICS FOR PREPARATION THEREOF

Номер: US20160030344A1
Принадлежит: Covaris, Inc.

The present disclosure relates to a composition that includes an apolipoprotein and a lipid bilayer, and methods and systems for preparing the composition. The apolipoprotein may be incorporated within at least a portion of the lipid bilayer. The lipid bilayer may form a liposome or other suitable carrier for transporting the apolipoprotein. The apolipoprotein incorporated lipid bilayer may provide a suitable delivery vehicle for the apolipoprotein to the body. Compositions of the present disclosure may be formed by exposing a mixture of an apolipoprotein and a lipid formulation to focused acoustic energy which, in some embodiments, may result in a liposome that at least partially encapsulates the apolipoprotein. In some embodiments, apolipoprotein A-V may be incorporated within a liposome, where the apolipoprotein A-V is suitably bioactive, or therapeutic, when delivered to cells and/or into the body of a patient. 1. A method of preparing a lipid composition , comprising:providing a mixture including an apolipoprotein and a lipid formulation in a vessel;transmitting focused acoustic energy through a wall of the vessel such that at least a portion of the mixture is exposed to acoustic energy having a frequency of between about 100 kilohertz and about 100 megahertz at a focal zone having a size dimension of less than about 2 centimeters; andforming a liposome at least partially encapsulating the apolipoprotein by, at least in part, exposure of the mixture to the focal zone.2. The method of claim 1 , wherein a particle size of the liposome is between 10 nm and 500 nm.3. The method of claim 1 , wherein the liposome fully encapsulates the apolipoprotein.4. The method of claim 1 , wherein the apolipoprotein is integrated into a lipid bilayer of the liposome.5. The method of claim 1 , wherein transmitting focused acoustic energy includes operating an acoustic transducer at a duty factor of greater than or equal to 25% claim 1 , or between 40% and 90%.6. The method of ...

Подробнее
29-01-2015 дата публикации

CONTINUOUS COATING OF PELLETS

Номер: US20150030756A1
Принадлежит:

A continuous dosage form coating apparatus uses vibrational impulses to maintain a dosage forms in a fluid state to expose them to a coating material atomized by spraying.

Подробнее
01-02-2018 дата публикации

PHASE-STABLE, SPRAYABLE FRESHENING COMPOSITIONS COMPRISING SUSPENDED PARTICLES AND METHODS OF FRESHENING THE AIR OR A SURFACE WITH THE SAME

Номер: US20180028707A1
Принадлежит:

A freshening composition is provided. The freshening composition includes a plurality of particles, a structurant system, and an aqueous carrier. The composition has a spray shear viscosity, as measured according to the SPRAY SHEAR VISCOSITY TEST METHOD described herein, of less than about 0.025 Pa-s. The composition has a creep recovery ratio of at least about 0.1, as measured according to the CREEP RECOVERY RATIO TEST METHOD described herein, or a yield stress of greater than 0 Pa and less than 1.0 Pa, as measured by the YIELD STRESS TEST METHOD described herein. 1. A freshening composition comprisinga plurality of particles;a structurant system;an aqueous carrier,wherein the composition has a spray shear viscosity, as measured according to the SPRAY SHEAR VISCOSITY TEST METHOD described herein, of less than about 0.025 Pa-s,and wherein the composition has a creep recovery ratio of at least about 0.1, as measured according to the CREEP RECOVERY RATIO TEST METHOD described herein, or a yield stress of greater than 0 Pa and less than 1.0 Pa, as measured by the YIELD STRESS TEST METHOD described herein.2. The composition of claim 1 , wherein the spray shear viscosity is less than about 0.01 Pa-s.3. The composition of claim 1 , wherein the creep recovery is greater than about 0.2.4. The composition of claim 1 , wherein the yield stress is about 0.05 Pa to about 0.5 Pa.5. The composition of claim 1 , and wherein the composition has a creep recovery ratio of at least about 0.1 and a yield stress of greater than 0 Pa and less than 1.0 Pa.6. The composition of claim 1 , wherein the particle is a benefit agent delivery particle.7. The composition of claim 6 , wherein the benefit agent delivery particle comprises a polymer of acrylic acid or derivatives thereof.8. The composition of claim 1 , wherein the structurant system comprises a polysaccharide.9. The composition of claim 1 , wherein the structurant system comprises a first polysaccharide and a second polysaccharide ...

Подробнее
31-01-2019 дата публикации

SYSTEMS AND METHODS FOR CONTINUOUS MANUFACTURING OF LIPOSOMAL DRUG FORMULATIONS

Номер: US20190029959A1
Принадлежит:

The present disclosure provides systems and methods for the continuous production of liposomes. An example method includes (a) mixing a solution of lipid and organic solvent from one or more containers to create an organic solvent-lipid solution, (b) providing the organic solvent-lipid solution to a first inlet of an injection port at a first flow rate, wherein the first inlet is in fluid communication with a first conduit, (c) providing an aqueous solution to a second inlet of the injection port at a second flow rate, wherein the second inlet is in fluid communication with a second conduit, wherein the first conduit is positioned concentrically within the second conduit at an outlet of the injection port, and wherein the first conduit extends through the outlet of the injection port, and (d) mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes. 2. (canceled)3. The system of claim 1 , further comprising:one or more pressure tanks connected to the each of the one or more containers;a first set of one or more valves positioned between the one or more containers and the one or more pressure tanks;a second set of one or more valves in fluid communication with each of the one or more containers; andone or more flow meters positioned between each of the one or more pressure tanks and each of the one or more valves of the second set.4. The system of claim 1 , further comprising:one or more gear pumps positioned between the vessel and each of the one or more injection ports.5. The system of claim 4 , further comprising:one or more flow meters positioned between the vessel and the one or more gear pumps.6. The system of claim 1 , wherein the mixer is a static mixer combines solutions from each of the one or more containers.7. The system of claim 1 , wherein the first set of one or more valves are solenoid valves.8. The system of claim 1 , wherein the second set of one or more valves are proportioning valves.9. The system of claim 1 , ...

Подробнее
31-01-2019 дата публикации

RISPERIDONE-CONTAINING MICROCAPSULE, METHOD FOR PREPARING SAME AND RELEASE CONTROL METHOD

Номер: US20190029969A1
Принадлежит: NIPRO CORPORATION

A microcapsule contains a biodegradable polymer and risperidone and has a sustained release property. The biodegradable polymer contained in the microcapsule has a molecular weight corresponding to 85% or more of an initial molecular weight (Mw) of the biodegradable polymer. A method of producing the microcapsule is also disclosed. The method of producing a microcapsule has (A) a step of preparing a first phase by mixing a solution of a biodegradable polymer and a solution of risperidone which are prepared separately, (B) a step of, immediately after the preparation of the first phase, mixing the first phase with a second phase being an aqueous phase to prepare an emulsion, and (C) a step of subjecting the resulting emulsion to in-water drying. 1. A microcapsule comprising a biodegradable polymer and risperidone , whereinthe biodegradable polymer in the microcapsule has a molecular weight (Mw) corresponding to 85% or more of an initial molecular weight (Mw) of the biodegradable polymer.2. The microcapsule of claim 1 , wherein the initial molecular weight (Mw) of the biodegradable polymer is not less than 50 claim 1 ,000 and less than 100 claim 1 ,000.3. A method for preparing a microcapsule comprising a biodegradable polymer and risperidone claim 1 , the method comprising:(A) a step of preparing a first phase by mixing a solution of the biodegradable polymer and a solution of the risperidone which have been prepared separately,(B) a step of, immediately after the preparation of the first phase, mixing the first phase with a second phase being an aqueous phase to prepare an emulsion, and(C) a step of subjecting the resulting emulsion to in-water drying.4. The method of claim 3 , wherein a molecular weight (Mw) of the biodegradable polymer in the microcapsule is a molecular weight (Mw) corresponding to 85% or more of an initial molecular weight (Mw) of the biodegradable polymer.5. The method of claim 3 , wherein the initial molecular weight (Mw) of the biodegradable ...

Подробнее
17-02-2022 дата публикации

SYSTEM AND METHOD FOR MAKING MICROSPHERES AND EMULSIONS

Номер: US20220047999A1
Принадлежит: OAKWOOD LABORATORIES, LLC

Various examples of systems and methods for making microspheres, microparticles, and emulsions are provided. In one example, a system and method for forming microspheres comprises: pumping a dispersed phase liquid and a continuous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase liquid and continuous phase liquid to a high shear environment within the impeller pump's pump chamber. In another example, a system and method for forming an emulsion comprises: pumping a dispersed phase liquid and an inner aqueous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase and the inner aqueous phase to a high shear environment within the impeller pump's pump chamber. 110-. (canceled)11. A method for making microspheres , the method comprising:providing a dispersed phase;providing a continuous phase; a housing,', 'a hollow interior, and', wherein the impeller includes a plurality of impeller blades and a base,', 'wherein the base includes a magnet to magnetically engage a rotating magnetic field outside of the chamber, and', 'wherein the impeller rotates and creates a direction of natural flow;, 'an impeller oriented within the hollow interior,'}], 'providing a chamber, the chamber includingpumping the dispersed phase under positive pressure into the chamber in a direction opposite the direction of natural flow;pumping the continuous phase under positive pressure into the chamber in a direction opposite the direction of natural flow; andhomogenizing the dispersed phase and the continuous phase within the chamber.12. The method of claim 11 , wherein the dispersed phase is pumped through a dispersed phase needle and into the chamber.13. The method of claim 11 , wherein the pumped dispersed phase and the pumped continuous phase contact the rotating impeller claim 11 , thereby creating a high shear environment within the hollow interior.14. The method of claim 11 , wherein the dispersed phase and the continuous phase ...

Подробнее
05-02-2015 дата публикации

Polarizable connection structure and device including the same

Номер: US20150034486A1
Автор: Hideyuki Sugioka
Принадлежит: Canon Inc

Provided is a device capable of functionalizing a micro-motion of a polarizable microstructure. A structure includes a plurality of polarizable structures, each having an electrically polarizable conductive part on a surface thereof, and a connector body having one of mobility and deformability, for connecting the plurality of polarizable structures to each other.

Подробнее
30-01-2020 дата публикации

METHOD TO PRODUCE COLORLESS, HIGH POROSITY, TRANSPARENT POLYMER AEROGELS

Номер: US20200031977A1
Принадлежит:

A method to produce a polymer gel includes dissolving precursors in a solvent to form a precursor solution, the precursors including polymer precursors, a stable free radical, one or more initiating radicals, and one or more stable free radical control agents, and heating the precursor solution to a temperature of polymerization to produce a cross-linked gel. A dried polymer aerogel has a Brunauer-Emmett Teller (BET) surface area over 100 m2/g, porosity of greater than 10%, visible transparency greater than 20%, color rendering index of over 20%, and average pore size of less than 100 nm. 1. A method to produce a polymer gel , comprising:dissolving precursors in a solvent to form a precursor solution, the precursors including polymer precursors, a stable free radical, one or more initiating radicals, and one or more stable free radical control agents; andheating the precursor solution to a temperature of polymerization to produce a cross-linked gel.2. The method of claim 1 , wherein the stable free radical control agent comprises one or more reducing agents.3. The method of claim 1 , wherein the stable free radical control agent comprises one or more time-controlled decomposing initiators.4. The method of claim 1 , wherein the stable free radical control agent comprises a mixture of one or more reducing agents and one or more time-controlled decomposing initiators.5. The method of claim 1 , further comprising mixing and deoxygenating the mixture of precursors in solvent.6. The method of claim 1 , wherein the polymer precursors comprise from at least one selected from a first group consisting of: difunctional monomers with two vinyl groups; crosslinkers with three or more vinyl groups; divinylbenzene claim 1 , tricyclodecane dimethanol diacrylate; hexanediol diacrylate; butanediol diacrylate; hexanediol dimethacrylate; butanediol dimethacrylate; trimethacryl adamantine; dipentaerythritol pentacrylate; and one of either alone or combined with at least one selected ...

Подробнее
11-02-2016 дата публикации

ENCAPSULATION OF MESSENGER RNA

Номер: US20160038432A1
Принадлежит:

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature. 1. A process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution , wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature.23-. (canceled)4. The process of claim 1 , wherein the pre-determined temperature is about 65° C.58-. (canceled)9. The process of claim 1 , wherein the mRNA solution and the lipid solution are mixed by a pulse-less flow pump.1012-. (canceled)13. The process of claim 1 , wherein the mRNA solution is mixed at a flow rate of about 200 ml/minute claim 1 , about 500 ml/minute claim 1 , about 1000 ml/minute claim 1 , about 2000 ml/minute claim 1 , about 3000 ml/minute claim 1 , about 4000 ml/minute claim 1 , or about 5000 ml/minute.14. (canceled)15. The process of claim 1 , wherein the lipid solution is mixed at a flow rate of about 50 ml/minute claim 1 , about 100 ml/minute claim 1 , about 150 ml/minute claim 1 , about 200 ml/minute claim 1 , about 250 ml/minute claim 1 , about 300 ml/minute claim 1 , about 350 ml/minute claim 1 , about 400 ml/minute claim 1 , about 450 ml/minute claim 1 , about 500 ml/minute claim 1 , about 550 ml/minute claim 1 , about 600 ml/minute claim 1 , about 650 ml/minute claim 1 , about 700 ml/minute claim 1 , about 750 ml/minute claim 1 , about 800 ml/minute claim 1 , about 850 ml/minute claim 1 , about 900 ml/minute claim 1 , about 950 ml/minute claim 1 , or about 1000 ml/minute.16. The process of claim 1 , wherein the process comprises a step of first generating the mRNA ...

Подробнее
24-02-2022 дата публикации

LIQUID ENCAPSULATION METHOD AND COMPOSITIONS AND USES RELATED THERETO

Номер: US20220055007A1
Принадлежит:

Present disclosure provides a method of forming a liquid-encapsulated core material, encapsulated core material compositions, and uses thereof, where the encapsulated core material is formed by providing an interfacial fluid layered on a host fluid, and passing a core material through the interfacial fluid and into the host fluid such that the interfacial fluid forms a shell around the core material. By so encapsulating the core material, it is protected from the host fluid. 1. A method of forming an encapsulated core material , the method comprising:providing an interfacial fluid and providing a host fluid, the interfacial fluid being layered on the host fluid; andpassing a core material having sufficient kinetic energy through the interfacial fluid and into the host fluid such that the interfacial fluid forms a shell around the core material,thereby forming the encapsulated core material.2. The method of claim 1 , wherein the core material has a density ρ claim 1 , the interfacial fluid has a density ρ claim 1 , the host fluid has a density ρ claim 1 , and wherein:{'br': None, 'sub': ['2', '3', '1'], '#text': 'ρ<ρ<ρ.'}3. The method of claim 1 , wherein the core material has a density ρ claim 1 , the interfacial fluid has a density ρ claim 1 , the host fluid has a density ρ claim 1 , and wherein:{'br': None, 'sub': ['1', '2', '3'], '#text': 'ρ>ρ>ρ.'}4. The method of any one of to claim 1 , wherein providing the interfacial fluid layered on the host fluid comprises providing a volume V of the interfacial fluid.5. The method of claim 4 , wherein the volume V is selected to provide the interfacial fluid layered on the host fluid.6. The method of or claim 4 , wherein the shell has a thickness T and modifying the volume V adjusts the thickness T.7. The method of any one of to claim 4 , wherein providing the interfacial fluid layered on the host fluid comprises dispensing the interfacial fluid on top of the host fluid.8. The method of claim 7 , wherein dispensing ...

Подробнее
09-02-2017 дата публикации

NITROGEN-DOPED CARBON AEROGELS FOR ELECTRICAL ENERGY STORAGE

Номер: US20170040123A1
Принадлежит:

Disclosed here is a method for making a nitrogen-doped carbon aerogel, comprising: preparing a reaction mixture comprising formaldehyde, at least one nitrogen-containing resorcinol analog, at least one catalyst, and at least one solvent; curing the reaction mixture to produce a wet gel; drying the wet gel to produce a dry gel; and thermally annealing the dry gel to produce the nitrogen-doped carbon aerogel. Also disclosed is a nitrogen-doped carbon aerogel obtained according to the method and a supercapacitor comprising the nitrogen-doped carbon aerogel. 1. A method for making a nitrogen-doped carbon aerogel , comprising:preparing a reaction mixture comprising formaldehyde, at least one nitrogen-containing resorcinol analog, at least one catalyst, and at least one solvent;curing the reaction mixture to produce a wet gel;drying the wet gel to produce a dry gel; andthermally annealing the dry gel to produce the nitrogen-doped carbon aerogel.2. The method of claim 1 , wherein the resorcinol analog is selected from (a) an aromatic compound comprising a nitrogen-containing ring linked to at least two hydroxyl groups and (b) an aromatic compound comprising a benzene ring or nitrogen-containing ring linked to at least one hydroxyl group and at least one amine group claim 1 , wherein the nitrogen-containing ring is selected from the group consisting of pyridine claim 1 , pyrazine claim 1 , pyrimidine claim 1 , pyridazine claim 1 , pyrrole claim 1 , pyrazole and imidazole.3. The method of claim 1 , wherein the resorcinol analog is pyridinediol.4. The method of claim 1 , wherein the resorcinol analog is aminophenol.5. The method of claim 1 , wherein the solvent is water and/or an organic solvent.6. The method of claim 1 , wherein the catalyst is selected from the group consisting of acetic acid claim 1 , nitric acid claim 1 , ascorbic acid claim 1 , hydrochloric acid claim 1 , sulfuric acid claim 1 , sodium carbonate claim 1 , sodium hydroxide claim 1 , ammonium hydroxide ...

Подробнее
18-02-2021 дата публикации

TOBACCO GRANULES AND METHOD OF PRODUCING TOBACCO GRANULES

Номер: US20210045430A1
Принадлежит: U.S. SMOKELESS TOBACCO COMPANY LLC

A smokeless tobacco product includes a plurality of orally disintegrable granules. Each granule has a core and at least one layer surrounding the core. The at least one layer includes tobacco particles and a binder. Also disclosed are methods of making tobacco granules that comprise a core and at least one layer having tobacco particles and a binder. 1. A smokeless tobacco product comprising a plurality of orally disintegrable granules , each granule having:a non-tobacco core, andat least one layer surrounding the core, the at least one layer comprising tobacco particles and a binder.267.-. (canceled) This application claims priority to Provisional U.S. Application Ser. No. 61/139,375, filed on Dec. 19, 2008, which is hereby incorporated by reference.This invention relates to tobacco granules and a method of producing the same.Smokeless tobacco products are orally consumed without subjecting the product to combustion. These products are manufactured in a variety of forms including chewing tobacco, dry snuff and moist snuff. Generally, these types of products are made as follows with the steps being in no particular order: cutting or grinding the tobacco into a suitable size; dipping or spraying the tobacco with a casing solution; partially drying the cased tobacco; holding the tobacco in containers for a period of time; and packaging the tobacco. See, for example, U.S. Pat. Nos. 4,528,993; 4,660,577; and 4,987,907.Snuffs are often marked as either “dry” or “moist.” Dry snuffs are generally finely ground and have a typical moisture content of about 8% by volume. Moist snuffs can have a variety of particle sizes and typically have a moisture content of about 40% to about 60% by weight.Smokeless tobacco products are often treated with a variety of flavors to provide a desirable taste experience. However, there remains a need for smokeless tobacco products with novel flavor characteristics.This disclosure describes a smokeless tobacco product that includes a plurality ...

Подробнее
18-02-2021 дата публикации

METHOD OF MAKING A CLEAR PERSONAL CARE COMPRISING MICROCAPSULES

Номер: US20210045979A1
Принадлежит:

The invention relates to a method of making a personal care composition, the method comprising steps of: providing a mixer comprising a housing comprising a first fluid inlet, a second inlet, and a fluid outlet, the mixer further rotor rotatably connected with the housing, the rotor comprising blades positioned within the housing to define cells between neighboring blades and the housing; preparing a personal care chassis base comprising surfactants and water; preparing a microcapsule composition comprising microcapsules, and air; advancing personal care chassis base along a flow path from the first fluid inlet toward the fluid outlet; transferring the microcapsule composition from the second inlet to the flow path by rotating the rotor; directing air in the microcapsule composition from inside the cells toward the second inlet; combining the microcapsule composition with the personal care chassis base to form the personal care composition; and advancing the personal care composition from the outlet. The microcapsule composition may further comprise an aqueous carrier including, but not limited to, water. The personal care composition can be transported to a filling line and filled through a filling nozzle into a bottle. 1. A method of making a personal care composition , the method comprising steps of:providing a mixer comprising a housing comprising a first fluid inlet, a second inlet, and a fluid outlet, the mixer further rotor rotatably connected with the housing, the rotor comprising blades positioned within the housing to define cells between neighboring blades and the housing;preparing a personal care chassis base comprising surfactants and water;preparing a microcapsule composition comprising microcapsules, and air;advancing personal care chassis base along a flow path from the first fluid inlet toward the fluid outlet;transferring the microcapsule composition from the second inlet to the flow path by rotating the rotor;directing air in the microcapsule ...

Подробнее
16-02-2017 дата публикации

METHOD FOR PRODUCING LIPOSOME

Номер: US20170042812A1
Принадлежит: FUJIFILM Corporation

Provided is a method for producing a liposome having safety and stability. According to the present invention, it is possible to provide a method for producing a liposome, including a step of mixing an oil phase with at least one lipid dissolved in an organic solvent and a water phase and stirring an aqueous solution containing the lipids, and a step of evaporating the organic solvent from the aqueous solution containing the liposomes obtained in the stirring step, in which the organic solvent is a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent. 1. A method for producing a liposome , comprising:a step of mixing an oil phase with at least one lipid dissolved in an organic solvent and a water phase and stirring an aqueous solution containing the lipids; anda step of evaporating an organic solvent from the aqueous solution containing liposomes obtained in the stirring step,wherein the organic solvent is a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent.2. The method for producing a liposome according to claim 1 , wherein the ester-based organic solvent is at least one selected from ethyl acetate claim 1 , methyl acetate claim 1 , isopropyl acetate claim 1 , t-butyl acetate claim 1 , or methyl propionate.3. The method for producing a liposome according to claim 1 , wherein the ester-based organic solvent is ethyl acetate.4. The method for producing a liposome according to claim 1 , wherein the water-soluble organic solvent is alcohols.5. The method for producing a liposome according to claim 2 , wherein the water-soluble organic solvent is alcohols.6. The method for producing a liposome according to claim 3 , wherein the water-soluble organic solvent is alcohols.7. The method for producing a liposome according to claim 4 , wherein the alcohol is at least one selected from ethanol claim 4 , methanol claim 4 , 2-propanol claim 4 , or t-butanol.8. The method for producing a liposome according to claim ...

Подробнее
19-02-2015 дата публикации

Enteric Coated Multiparticulate Composition With Proteinaceous Subcoat

Номер: US20150050352A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. 1. A method of treating a gastrointestinal disorder in a human subject , the method comprising administering to the subject a multiparticulate dosage form composition effective to treat a gastrointestinal disorder in the subject , the composition comprising a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings.2. The method of claim 1 , wherein administering is performed enterally.3. The method of claim 2 , wherein administering is performed orally.4. The method of claim 1 , wherein the one or more terpene-based active ingredients include L-menthol from an at least 80% pure L-menthol source dissolved in a terpene-containing essential oil.5. The method of claim 1 , wherein the one or more terpene-based active ingredients include both L-menthol and caraway oil.6. The method of claim 1 , wherein the one or more terpene-based active ingredients include L-menthol from an at least 80% pure L-menthol source dissolved in peppermint oil.7. The method of claim 1 , wherein the one or more terpene-based active ingredients include both peppermint oil and caraway oil.8. The method of claim 1 , wherein the one or more terpene-based active ingredients include both L-menthol and ...

Подробнее
03-03-2022 дата публикации

THERMALLY TREATED POLYAMIC AMIDE AEROGEL

Номер: US20220064399A1
Принадлежит:

Thermally treated aerogel compositions that include polyamic amides in an amount less than the aerogel compositions that include polyamic amides prior to thermal treatment, and articles of manufacture that include or are manufactured from the aerogel compositions are described.

Подробнее
25-02-2021 дата публикации

METHOD AND APPARATUS FOR MANUFACTURING FLAVOR CAPSULE OF TOBACCO

Номер: US20210051996A1
Принадлежит:

An apparatus for manufacturing a flavor capsule of tobacco according to an embodiment of the present disclosure may comprise: a membrane tank for storing a membrane; a flavored liquid tank for storing a flavored liquid; and a nozzle to which the membrane is supplied from the membrane tank, to which the flavored liquid is supplied from the flavored liquid tank, and through which the flavored liquid is discharged while being enveloped in the membrane, so as to form the initial shape of a flavor capsule, wherein the membrane tank is equipped with a temperature adjustment unit for lowering the temperature of the membrane tank over time in order to preserve the viscosity of the membrane. 1. An apparatus for manufacturing a fragrance capsule of a cigarette , the apparatus comprising:a capsule manufacturer including a membrane tank configured to store a membrane, a fragrant liquid tank configured to store a fragrant liquid, and a nozzle connected to the membrane tank and the fragrant liquid tank through respective supply lines, and configured to form an initial form of the fragrance capsule by discharging the membrane transferred from the membrane tank and the fragrant liquid transferred from the fragrant liquid tank such that the membrane wraps the fragrant liquid; anda first hardener configured to first harden the fragrance capsule manufactured by the capsule manufacturer,wherein a thickness of the membrane of the fragrance capsule manufactured by the capsule manufacturer is 0.5 to 0.8 millimeter (mm).2. The apparatus of claim 1 , wherein claim 1 , by setting the thickness of the membrane of the fragrance capsule manufactured by the capsule manufacturer to be 0.5 to 0.8 mm claim 1 , a crush strength of the fragrance capsule is adjusted to 0.8 to 2.0 kilogram-force (kgf).3. The apparatus of claim 1 , further comprising:a second hardener configured to secondarily harden the fragrance capsule dried by a dryer after being hardened by the first hardener.4. The apparatus of ...

Подробнее
14-02-2019 дата публикации

Multi-Disk Spinning Disk Assembly for Atomization and Encapsulation

Номер: US20190046940A1
Принадлежит:

A multi-disk spinning disk assembly for atomization and encapsulation applications. A number of disks and spacers () are stacked to form a disk stack having a feed well in the center core of the stack. The fluid to be atomized or encapsulated is delivered to the feed well . The fluid then flows into spacer channels () within or on the surface of the spacers. The channels () communicate the fluid toward the outer edges of the disks . The disk surface past the spacers () can have various configurations, such as teeth, weirs, or a bigger or smaller diameter, as desired for particular atomization or encapsulation characteristics. 1. A multi-disk spinning disk assembly for atomizing or encapsulating fluids during rotation of the assembly , comprising:a disk stack, comprising a number of annular disks arranged one atop the other, each disk having a center opening;an annular spacer associated with each disk, each spacer having a center opening and having a radius the same as or smaller than that of each disk;the disk stack further comprising a spacing disk between adjacent annular disks, each spacing disk having a center opening the same size as the center opening of the annular disks and having a radius the same as or smaller than that of the annular disks;wherein the spacing disks provide a gap between the annular disks from which the fluid exits circumferentially from the disk stack when the disk stack is rotating;wherein the spacing disks are removeable from, and exchangeable in, the disk stack;an inner well within the disk stack, the inner well defined by arranging the spacers between disks such that the center openings of the spacers, the center openings of the annular disks, and the center openings of the spacing disks form the inner well, and such that the inner well is perpendicular to the plane of the disks; andwherein each spacer has solid portions extending radially from the inner well toward the outer edge of the spacer, each solid portion blocking flow of the ...

Подробнее
08-05-2014 дата публикации

Device for Purifying Exhaust Gases from a Heat Engine, Comprising a Catalytic Ceramic Support Comprising an Arrangement of Essentially Identical Crystallites

Номер: US20140127099A1

Device for purifying exhaust gases from a thermal combustion engine, comprising a catalytic ceramic carrier comprising an arrangement of crystallites of the same size, same isodiametric morphology and same chemical composition or substantially the same size, same isodiametric morphology and same chemical composition, wherein each crystallite is in contact at a singular or almost singular point with surrounding crystallites, and whereon at least one active phase is deposited for the chemical destruction of impurities in the exhaust gas.

Подробнее
23-02-2017 дата публикации

Dosing Preparation of Dabigatran Etexilate or a Salt Thereof and a Preparation Method Thereof

Номер: US20170049764A1
Автор: SHENG Xiaoxia, Tang Yong
Принадлежит: SOLIPHARMA LLC

Disclosed is an oral dosing preparation of dabigatran etexilate or pharmaceutically acceptable salts thereof and a preparation method thereof. 1. A pharmaceutical composition for oral administration comprising:a) one or more approximately spherically-shaped pellet cores consisting of a binder and pharmaceutically acceptable celluloses or sugars or starches or one or more component(s) consisting of microcrystalline celluloses or sugars or starches;b) a first active substance layer consisting of an active substance, and/or a disintegrant, and/or a filler and a binder, wherein the active substance is dabigatran etexilate or one pharmaceutically acceptable salt thereof;c) a first water soluble isolating layer surrounding the surface of the first active substance layer, wherein the layer material is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, starch, resin, and other organic polymer materials or combinations of these polymers;d) an acid layer consisting of a binder and a pharmaceutically acceptable organic acid, or consisting of an organic acid, wherein the organic acid has a solubility more than 1 g/250 ml in water at 20° C., and is selected from the group consisting of tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, glutamic acid or aspartic acid or a hydrate or salt of glutamic acid or aspartic acid, and hemi-cysteine hydrochloride;e) a second water soluble isolating layer on the surface of acid layer, wherein the layer material is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, starch, resin and other water soluble polymers or combinations of these polymers;f) a second active substance layer consisting of an active substance, and/or a disintegrant, and/or a filler and a binder, wherein the active substance is dabigatran etexilate or one pharmaceutically acceptable salt thereof; andg) a third water soluble isolating layer on the surface of the second ...

Подробнее
25-02-2021 дата публикации

SOFT MAGNETIC MATERIAL POWDER AND MANUFACTURING METHOD THEREOF, AND MAGNETIC CORE AND MANUFACTURING METHOD THEREOF

Номер: US20210054218A1
Автор: ISHIDA Yuya
Принадлежит: MURATA MANUFACTURING CO., LTD.

A soft magnetic material powder includes soft magnetic material particles, the soft magnetic material particles each include a core formed from an Fe-based soft magnetic material and an insulating film covering the surface of the core, and the insulating film contains an inorganic oxide and a water soluble polymer. A magnetic core includes soft magnetic material particles and a binder bonding the soft magnetic material particles to each other, the soft magnetic material particles each include a core containing an Fe-based soft magnetic material and an insulating film covering the surface of the core, and the insulating film contains an inorganic oxide and a water soluble polymer. 1dispersing an Fe-based soft magnetic material in a solvent; andadding a metal alkoxide, a water soluble polymer, and water to the solvent followed by stirring to form insulating films each containing a metal oxide, which is a hydrolysate of the metal alkoxide, and the water soluble polymer on surfaces of soft magnetic material particles which form the Fe-based soft magnetic material powder, so that an insulating treatment is performed on the soft magnetic material particles.. A method for manufacturing a soft magnetic material powder, the method comprising: This application is Continuation of U.S. patent application Ser. No. 16/861,037 filed Apr. 28, 2020, which is a Divisional of U.S. patent application Ser. No. 15/434,488 filed Feb. 16, 2017, which claims benefit of priority to Japanese Patent Application 2014-209308 filed Oct. 10, 2014, and to International Patent Application No. PCT/JP2015/075945 filed Sep. 14, 2015, the entire content of which is incorporated herein by reference.The present disclosure relates to a soft magnetic material powder used for a magnetic core and a manufacturing method thereof. In addition, the present disclosure also relates to a magnetic core using this soft magnetic material powder and a manufacturing method of the magnetic core.In recent years, in ...

Подробнее
26-02-2015 дата публикации

MICROSPHERE COMPOSITIONS, PREPARATION METHOD AND APPLICATIONS THEREOF

Номер: US20150056290A1
Принадлежит:

A cell carrying microsphere composition, wherein the microsphere composition comprises a microspheric core comprising a triblock copolymer matrix A-B-A wherein A is selected from poly(lactide-co-glycolide) (PLGA) or polylactide (PLA) and B is poloxamer or poloxamine, wherein the microspheric core is coated with a cell adhesion coating and further comprises whole cells or cell fragments bonded to the cell adhesion coating, a process for the preparation of a cell carrying microsphere composition, and applications thereof. 1. A cell carrying microsphere composition , wherein the microsphere composition comprises a microspheric core comprising a triblock copolymer matrix A-B-A wherein A is selected from poly(lactide-co-glycolide) (PLGA) or polylactide (PLA) and B is poloxamer or poloxamine , wherein the microspheric core is coated with a cell adhesion coating and further comprises whole cells or cell fragments bonded to the cell adhesion coating.2. A cell carrying microsphere composition according to claim 1 , wherein A is poly(lactide-co-glycolide) (PLGA).3. A cell carrying microsphere composition according to claim 1 , wherein B is a poloxamer.4. A cell carrying microsphere composition according to claim 1 , wherein the proportion of poloxamer or poloxamine in the triblock copolymer is between 2 and 40% (w/w).5. A cell carrying microsphere composition according to claim 1 , comprising whole cells.6. A cell carrying microsphere composition according to claim 1 , further comprising an active ingredient embedded within the microspheres7. A cell carrying microsphere composition according to claim 6 , wherein the active ingredient is a protein.8. A cell carrying microsphere composition according to claim 1 , wherein the cell adhesion coating comprises fibronectine and poly-D-lysine.10. A process for the preparation of a cell carrying microsphere composition of claim 6 , comprising the steps consisting inproviding a solution of a A-B-A (preferably poly(D,L-lactide-co- ...

Подробнее
26-02-2015 дата публикации

SILK NANOSPHERES AND MICROSPHERES AND METHODS OF MAKING SAME

Номер: US20150056293A1
Принадлежит: TRUSTEES OF TUFTS COLLEGE

The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles. In particular, the silk spheres are prepared from phase separation of silk and polyvinyl alcohol (PVA), without exposure to an organic solvent. The method employs a chemical, PVA, which is an FDA-approved ingredient in drug formulations. Different parameters can be adjusted to control the size and shape of the silk spheres during the fabrication process. The silk particle compositions of the present invention may also encapsulate active agents or chemicals. Such compositions allow the active agents to be controllably and sustainably released to the target organs or tissues. The silk composition entrapping active agents also provides for a long-term storage medium for the active agents so entrapped. The silk nano- and microparticles of the present invention are thus suitable for a variety of biomedical and pharmaceutical applications, such as drug delivery or tissue engineering. 1. A method of preparing silk spheres with the size of spheres ranging from nanometers to micrometers , comprising:(a) mixing an aqueous silk fibroin solution with an aqueous PVA solution;(b) drying the solution of step (a) to form a film;(c) dissolving the film in water; and(d) removing at least a portion of the PVA, thereby forming silk spheres with the size of the spheres ranging from nanometers to micrometers.2. (canceled)3. The method of claim 1 , further comprising applying constraints on the silk/PVA blend film before dissolving the film in water to change the shape of the silk spheres.4. The method of claim 1 , further comprising stretching the silk/PVA blend film before dissolving the film in water claim 1 , thereby forming a spindle-shaped silk sphere.5. The method of claim 1 , further comprising water-annealing the silk/PVA blend film before dissolving the film ...

Подробнее